influenza

Search with Google Search with Bing
Information
Disease name
influenza
Disease ID
DOID:8469
Description
"A viral infectious disease that results in infection, located in respiratory tract, has_material_basis_in Influenzavirus A, has_material_basis_in Influenzavirus B, or has_material_basis_in Influenzavirus C, which are transmitted_by droplet spread of oronasal secretions during coughing, sneezing, or talking from an infected person. It is a highly contagious disease that affects birds and mammals and has_symptom chills, has_symptom fever, has_symptom sore throat, has_symptom runny nose, has_symptom muscle pains, has_symptom severe headache, has_symptom cough, and has_symptom weakness." [url:http\://www.merck.com/mmhe/sec17/ch198/ch198d.html, url:http\://www.who.int/mediacentre/factsheets/2003/fs211/en/]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
Genes Mutation Description Source Links
NCT ID Status Phase Summary Start date Completion date
NCT04164212 Active, not recruiting Phase 4 Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection September 1, 2020 December 31, 2024
NCT05827926 Active, not recruiting Phase 1/Phase 2 A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults April 14, 2023 December 2, 2024
NCT05787964 Active, not recruiting Immunity to Infection in Healthy Participants and Participants With Cancer October 1, 2022 September 1, 2024
NCT05606965 Active, not recruiting Phase 2 A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults November 2, 2022 August 9, 2024
NCT06097273 Active, not recruiting Phase 3 A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age October 19, 2023 June 14, 2024
NCT05012189 Active, not recruiting Phase 4 Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks August 6, 2021 December 2023
NCT06030726 Active, not recruiting N/A Nationwide Utilization of Danish Government Electronic Letter System for Confirming the Effectiveness of Behavioral Nudges in Increasing InFLUenza Vaccine Uptake Among Older Adults September 14, 2023 May 31, 2024
NCT06062264 Active, not recruiting N/A Patient Portal Flu Vaccine Reminders (RCT 6) October 3, 2023 April 1, 2024
NCT06286488 Active, not recruiting Phase 4 Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza September 15, 2020 May 1, 2026
NCT03598439 Active, not recruiting Phase 4 Randomized Influenza Vaccine Evaluation of Immune Response July 30, 2018 December 30, 2023
NCT05190432 Active, not recruiting N/A Taxifolin/Ergothioneine and Immune Biomarkers in Healthy Volunteers (TaxEr) November 10, 2021 August 2024
NCT06208683 Active, not recruiting Phase 4 The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students November 4, 2023 December 1, 2024
NCT02860039 Active, not recruiting Phase 2 High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant September 2016 September 2024
NCT05972174 Active, not recruiting Phase 1/Phase 2 A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults July 10, 2023 July 26, 2024
NCT06091410 Active, not recruiting Phase 4 Immunogenicity of Concomitant Administration of COVID-19 Vaccines With Influenza Vaccines September 25, 2023 June 25, 2025
NCT03965195 Active, not recruiting Phase 4 Recombinant Influenza Vaccination in U.S. Nursing Homes July 20, 2019 December 2023
NCT01021098 Active, not recruiting Acute Respiratory Infection Consortium November 2009 December 2023
NCT06030739 Active, not recruiting N/A Nationwide Utilization of Danish Government Electronic Letter System for Increasing InFLUenza Vaccine Uptake Among Adults With Chronic Disease September 24, 2023 May 31, 2024
NCT05895955 Active, not recruiting Phase 1/Phase 2 Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais November 4, 2023 July 31, 2025
NCT03753347 Active, not recruiting Phase 4 TITRE III: Influenza B Immunogenicity Investigation December 1, 2018 June 30, 2024
NCT06178991 Active, not recruiting Phase 3 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza. December 20, 2023 November 14, 2024
NCT03734237 Active, not recruiting Phase 4 A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD November 6, 2018 May 31, 2024
NCT06054269 Active, not recruiting Phase 3 Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP November 4, 2022 March 31, 2026
NCT04974775 Active, not recruiting Swecrit Biobank - Blood Samples From Critically Ill Patients and Healthy Controls June 2014 December 31, 2024
NCT00161837 Completed Phase 2/Phase 3 Comparison of the Safety and Immune Response of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2003/2004 December 2003 July 2004
NCT00170443 Completed Phase 2 Trivalent rHA Dose Escalation Study in Elderly Subjects June 2004
NCT00170482 Completed Elderly Influenza Vaccine Immunogenicity Substudy April 25, 2005 May 30, 2005
NCT00170508 Completed N/A Young Adult Influenza Vaccine Immunogenicity Substudy June 2005 August 2005
NCT00170547 Completed Phase 2 Comparison of Delivery Routes of Flu Vaccine in Adults September 2005 February 2006
NCT00192127 Completed Phase 3 Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults August 2004 February 2005
NCT00192140 Completed Phase 4 Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age June 2004 January 2005
NCT00192153 Completed Phase 2 Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older July 2001 October 2001
NCT00192166 Completed Phase 2 Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months October 2002 May 2003
NCT00192179 Completed Phase 2 A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years. June 2003 July 2003
NCT00192192 Completed Phase 3 Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults November 2000 December 2000
NCT00192218 Completed Phase 4 Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program October 2004 April 2005
NCT00192231 Completed Phase 3 Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T) April 2001 June 2001
NCT00192283 Completed Phase 3 Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold- Adapted (CAIV-T) in Healthy Children Attending Day Care Centers September 2000 May 2002
NCT00192309 Completed Phase 2 Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine. September 2001 December 2001
NCT00192322 Completed Phase 2 Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children September 2001 December 2001
NCT00192361 Completed Phase 3 Trial of the Safety, Transmissibility, and Phenotypic and Genotypic Stability of Influenza Virus Vaccine,(CAIV-T), in Children Who Attend Day Care. (Final Report Version 2.0) November 1999
NCT00192387 Completed Phase 2 Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T) September 2001 December 2001
NCT00192413 Completed Phase 3 Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza March 2002 November 2002
NCT00192426 Completed Phase 3 Trial to Evaluate the Immune Response to OPV When Administered Concomitantly With CAIV-T to Healthy Children. September 2001 December 2001
NCT00192491 Completed Phase 3 Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children December 2000 December 2003
NCT00197223 Completed Phase 3 Post-marketing Study to Evaluate the Efficacy of Influenza Vaccine September 2005 May 2006
NCT00197288 Completed Phase 3 Study Comparing the Immune Response of Fluarix and Fluzone Influenza Vaccines October 2005 June 2006
NCT00197301 Completed Phase 1/Phase 2 Liposomal Based Intranasal Influenza Vaccine:Safety and Efficacy October 2005 April 2006
NCT00205270 Completed Influenza Vaccine in Lung Transplant Patients December 2004 July 2009
NCT00213967 Completed N/A The Effect of Needle Temperature on Pain Ratings Following Intramuscular Injection October 2005 January 2007
NCT00217230 Completed Phase 3 Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older April 2001 November 2001
NCT00221676 Completed Phase 4 Effectiveness of Influenza Vaccination Among General Practitioners July 2002 June 2004
NCT00230750 Completed Phase 1/Phase 2 Inactivated Influenza A/H5N1 Vaccine in the Elderly October 2005 January 2007
NCT00231907 Completed Phase 1 A Phase I Safety and Immunogenicity Study of Mix and Match of Licensed Flu Vaccine and Flumist September 2005 March 2007
NCT00231920 Completed Phase 1 Inactivated Influenza Vaccine in Infants 10-22 Weeks of Age October 2004 October 2006
NCT00232947 Completed Phase 3 Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and Over October 2005 February 2006
NCT00240877 Completed Phase 3 Study to Evaluate the Safety of a Monovalent Vaccine of a New 6:2 Reassortant in Healthy Adults (AV024) August 2002 April 2004
NCT00240903 Completed Phase 1 Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine October 2005 March 2006
NCT00240968 Completed Phase 2 H5 Booster After a Two Dose Schedule October 2005 July 2006
NCT00253734 Completed Phase 2 Immunogenicity and Safety of Different Doses of Fluzone® Influenza November 2005 November 2006
NCT00258817 Completed Phase 4 Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone Vaccine October 2005 August 2007
NCT00258830 Completed Phase 4 Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine September 2005 March 2007
NCT00258934 Completed Phase 2 Immunogenicity Study of the Influenza Vaccine in Adults September 2005 September 2008
NCT00263900 Completed N/A TGV:Use of the Quick Diagnostic Test of the Influenza and the Infection With RSV by the Paediatric Emergency Unit December 2005 June 2010
NCT00280033 Completed Phase 1/Phase 2 H5 Adult - Chiron Study of Bird Flu Vaccine February 2006 November 2006
NCT00283283 Completed Phase 2 Comparison of Full-dose Flu Vaccine to Half-dose Flu Vaccine November 2004 May 2006
NCT00289510 Completed Phase 1/Phase 2 Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell Derived) January 2006
NCT00294099 Completed Phase 1/Phase 2 H5 Vaccine Alone or With Aluminum Hydroxide in Elderly Adults March 2006 March 2007
NCT00296634 Completed Phase 1/Phase 2 H5 Vaccine Alone or With Adjuvant in Healthy Adults March 2006 December 2006
NCT00296829 Completed Phase 2 Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the Elderly January 2006 February 2007
NCT00297050 Completed Phase 1 Safety and Dose Study of Peramivir for Influenza Treatment February 23, 2006 November 14, 2006
NCT00298233 Completed Phase 2 High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza February 2006 January 2010
NCT00304434 Completed Phase 4 Evaluation of Alternative Oseltamivir (Tamiflu) Dosing Strategies. February 2005 February 2007
NCT00306527 Completed Phase 3 Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly September 2005 April 2006
NCT00306943 Completed Phase 3 Annual Study for Fluarix Registration July 2005 August 2005
NCT00306982 Completed Incidence of Influenza, Downstream Complications of Influenza & Hospitalizations in Elderly Vaccinated With Fluarix™ March 2006 December 2006
NCT00306995 Completed Phase 2 Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population May 11, 2005 July 4, 2006
NCT00307177 Completed Phase 2 Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma August 2004 April 2005
NCT00309634 Completed Phase 1 Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years March 27, 2006 October 28, 2006
NCT00309647 Completed Phase 1 Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age March 29, 2006 November 16, 2006
NCT00310206 Completed Phase 1 H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults July 2005 October 2006
NCT00310648 Completed Phase 3 Comparative Trial Evaluating Safety and Immunogenicity of an Adjuvanted and a Conventional Influenza Vaccine in Elderly Subjects (> 60 Years) January 2006
NCT00310804 Completed Phase 3 Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60) September 2005 April 2006
NCT00311428 Completed Phase 4 Safety and Immunogenicity of Three Commercially Available Influenza Vaccines in Children Aged 6 to <36 Months October 2005
NCT00311649 Completed Phase 1/Phase 2 Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities November 2005 September 2006
NCT00311675 Completed Phase 1/Phase 2 St. Jude Open Label H5 Trial April 2006 December 2006
NCT00311701 Completed Chart Review of Antivirals for Influenza in Infants November 2005 December 2006
NCT00311714 Completed Phase 1 Safety, Tolerability and Pharmacokinetic Study of Biota-CS-8958 April 2007 December 2007
NCT00311727 Completed N/A Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine October 2005 March 2006
NCT00316628 Completed Phase 2 Safety and Immunogenicity of an Adjuvanted Influenza Vaccine in Subjects Aged 65 Years and Over. June 2005
NCT00318058 Completed Phase 1 Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza Disease in the Elderly Population October 3, 2005 November 4, 2005
NCT00318149 Completed Phase 2 Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population October 10, 2005 May 14, 2006
NCT00319098 Completed Phase 3 Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above May 1, 2006 July 31, 2007
NCT00320346 Completed Phase 2 Phase II Study of Pandemic Influenza Vaccine July 2006 September 2006
NCT00321373 Completed Phase 2 Study to Evaluate an Influenza Vaccine Candidate May 11, 2006 July 18, 2006
NCT00321763 Completed Phase 2 Study to Demonstrate the Lot-to-lot Consistency and to Evaluate the Safety of an Adjuvanted Influenza Vaccine Candidate April 27, 2006 July 7, 2006
NCT00328107 Completed Phase 2/Phase 3 Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults November 2004 August 2005
NCT00329927 Completed Phase 2 Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Elderly Subjects June 2006
NCT00329966 Completed Phase 2 Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older June 2006
NCT00333398 Completed Phase 3 Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults June 2006 August 2006
NCT00334529 Completed Phase 2 Alternative Oseltamivir Dosing Strategies June 5, 2006 April 10, 2007
NCT00336453 Completed Phase 1/Phase 2 Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics October 2006 July 2007
NCT00337896 Completed T and B Cell Response to Avian Flu Vaccine March 2006 May 2006
NCT00343681 Completed Phase 2 A Study of the Immunogenicity and Safety of the 2006-2007 Influenza Vaccine July 2006 August 2007
NCT00345904 Completed Phase 3 Study to Evaluate the Safety and Immunogenicity of Fluarix™ 2006/2007 in Adults Aged 18 Years or Above July 2006 August 2006
NCT00347672 Completed Phase 1 Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults June 2006 July 2007
NCT00348881 Completed Phase 3 Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants June 2006 June 2008
NCT00349037 Completed Phase 1 Study of the Ability of a Flu Vaccine to Prevent Flu Infection September 2006 January 2007
NCT00349141 Completed Phase 1/Phase 2 Safety and Immunogenicity Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived) June 2006
NCT00354016 Completed Phase 3 Safety and Immunogenicity of Preservative Free Inactivated Split Influenza Vaccine, Using the Strain Composition 2006/2007 in Non-Elderly Adult and Elderly Subjects July 2006
NCT00356798 Completed Phase 1 Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy Subjects December 2005 April 2006
NCT00363077 Completed Phase 2 Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate October 2, 2006 November 17, 2006
NCT00363870 Completed Phase 4 A Study to Demonstrate the Efficacy of GSK Biologicals' Influenza Vaccine in Adults September 2006 June 2007
NCT00370864 Completed Phase 2 Study of a Pandemic Influenza Vaccine in Children September 2006 July 2007
NCT00372255 Completed Phase 4 Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005/2006 in Children Aged 6 - 13 Years November 17, 2005 March 28, 2006
NCT00374842 Completed Phase 2 Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmithKline (GSK) Biologicals' GSK1247446A Low Dose Influenza Vaccine Candidate October 3, 2006 November 30, 2006
NCT00375115 Completed Phase 4 Efficacy of Sambucol in the Treatment of Influenza September 2006 September 2009
NCT00375206 Completed Phase 1 A Safety and Immunology Study of a DNA Trivalent Influenza Vaccine September 2006 January 2007
NCT00376402 Completed Phase 2 Study of a Pandemic Influenza Vaccine in Elderly Participants October 2006 June 2007
NCT00377585 Completed Phase 2 Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population September 22, 2006 January 30, 2007
NCT00377611 Completed Phase 4 Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™ October 5, 2006 June 20, 2007
NCT00380211 Completed Phase 3 Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults September 2006 November 2006
NCT00380237 Completed Phase 1 Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B) October 2006 January 2007
NCT00382187 Completed Phase 2 Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in Adults November 2006 January 2008
NCT00382980 Completed Phase 1 Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults October 2006 September 2007
NCT00383123 Completed Phase 3 Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in Children November 2, 2006 October 19, 2007
NCT00383526 Completed Phase 3 Study of Inactivated, Split-Virion Influenza Vaccine Compared With the Reference Vaccine Vaxigrip® in the Elderly September 2006 September 2009
NCT00383539 Completed Phase 3 Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in Adults September 2006 December 2007
NCT00385281 Completed Phase 4 Proteomic Profiling for Influenza Vaccination - FluMist October 2006 April 2007
NCT00385840 Completed Phase 2 Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate October 20, 2006 February 5, 2007
NCT00386113 Completed Phase 2 Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly October 16, 2006 November 14, 2006
NCT00386542 Completed Phase 1/Phase 2 Needle-free Jet Injection of Reduced-dose, Intradermal, Influenza Vaccine in >= 6 to < 24-month-old Children October 2006 May 2010
NCT00386698 Completed Phase 2 Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly Adults October 2006 December 2006
NCT00388583 Completed Phase 2 Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects September 2006 September 2008
NCT00389532 Completed Phase 4 Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine October 2006 September 2008
NCT00389857 Completed Phase 4 Trial to Collect Safety Data and Sera for Immunogenicity Testing October 2006 July 2008
NCT00390884 Completed Phase 4 Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation. October 2006 September 2008
NCT00391053 Completed Phase 3 Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly October 2006 February 2008
NCT00391391 Completed Phase 2 Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children October 2006 October 2007
NCT00391768 Completed Phase 1/Phase 2 Oseltamivir Treatment for Children Less Than 24 Months of Age With Influenza January 2007 April 2010
NCT00395174 Completed Phase 3 Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults October 2006 May 2007
NCT00397215 Completed Phase 2 Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age November 17, 2006 September 14, 2009
NCT00401700 Completed Influenza Vaccine Postpartum Questionnaire October 2006 July 2009
NCT00402649 Completed Phase 1/Phase 2 Open-Label Study of H5 Vaccine in Participants of Protocol 04-077 February 2007 December 2007
NCT00404664 Completed N/A Improving Influenza Vaccination Rates Among Health Care Professionals September 2004 April 2005
NCT00408395 Completed Phase 2 Safety and Immunogenicity of 2 Commercially Available Influenza Vaccines in Children November 2006 August 2007
NCT00412555 Completed Phase 4 A Study of Tamiflu (Oseltamivir) for Seasonal Prophylaxis of Influenza in Children. December 2006 May 2007
NCT00412737 Completed Phase 4 A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised Participants January 2007 May 2008
NCT00415129 Completed Phase 2 Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly June 2006 March 2009
NCT00419224 Completed Phase 4 Influenza Vaccination in Bone Marrow Transplantation October 2002 April 2003
NCT00419263 Completed Phase 2 Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza. January 2007 September 2007
NCT00419861 Completed Inpatient Influenza Surveillance November 2006 April 2007
NCT00421837 Completed Pilot Study of Genotypic Analysis May 2007 December 2008
NCT00424086 Completed Phase 1/Phase 2 Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) January 2007 September 2007
NCT00425893 Completed N/A A Randomised Controlled Trial of Face Masks and Hand Hygiene in Reducing Influenza Transmission in Households February 2007 November 2008
NCT00428493 Completed Prospective Study of AI H5N1 in China January 2007 January 2008
NCT00428753 Completed China Case Control Avian Influenza January 2007 January 2008
NCT00428831 Completed Clinical IGSP-CHOP Boston February 2007 September 2008
NCT00430521 Completed Phase 2 Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A) February 5, 2007 October 20, 2008
NCT00434733 Completed Phase 3 Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects January 2007
NCT00436046 Completed Phase 1 Interferon as a Mucosal Adjuvant for Influenza Vaccine Given Intranasally March 2007 October 2007
NCT00439335 Completed Phase 1/Phase 2 Higher Dose Intradermal H5 Vaccine March 2007 February 2008
NCT00440362 Completed Phase 1/Phase 2 A Phase 1/2 Clinical Trial of an Alphavirus Replicon Vaccine for Influenza April 2007 September 2007
NCT00442975 Completed Phase 4 Response of Older Adults to Influenza Vaccination With Regard to Cytomegalovirus (CMV) Status March 2007 September 2007
NCT00446628 Completed N/A Project to Investigate Ways to Reduce the Spread of Influenza in Schools and Households With Children January 2007 September 2009
NCT00448773 Completed Phase 4 REDucing Influenza Among University Students, University of California at Berkeley February 2007 May 2008
NCT00449670 Completed Phase 3 Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults March 24, 2007 June 10, 2008
NCT00453999 Completed Phase 2 Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza July 2007 August 2009
NCT00455169 Completed Influenza Vaccine in Premature Infants October 2007 May 2008
NCT00462215 Completed Phase 3 Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived) April 2007 February 2010
NCT00464672 Completed Phase 3 Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old April 2007 December 2007
NCT00476307 Completed Phase 3 Immunogenicity and Reactogenicity of Fluarix™ (Influsplit SSW®) 2007/2008 in People 18 Years Old or Above June 2007 July 2007
NCT00479648 Completed Phase 2 A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants May 2007 August 2007
NCT00488046 Completed Phase 1 Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults June 2007 September 2007
NCT00490633 Completed N/A Intervention Study of Face Mask and Hand Sanitizer to Reduce Influenza Transmission October 2006 April 2008
NCT00491257 Completed Phase 2 A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine June 2007 July 2007
NCT00491283 Completed N/A QuickVue Influenza A+B Clinical Field Trial July 2006 August 2006
NCT00491985 Completed Phase 2 Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children June 2007 June 2010
NCT00492063 Completed Phase 3 Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly September 2004 May 2005
NCT00502593 Completed Phase 2 Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children July 23, 2007 December 4, 2009
NCT00504231 Completed Phase 2 Intradermal Influenza Vaccine Study in Elders September 2007 January 2008
NCT00505453 Completed Phase 3 A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral® Vaccine July 2007 August 2007
NCT00506350 Completed Phase 2 Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults August 1, 2007 October 12, 2009
NCT00510874 Completed Phase 1 Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults July 28, 2007 October 24, 2008
NCT00514709 Completed Phase 3 Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants September 2007 April 2009
NCT00516035 Completed Phase 1 Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults September 2007 December 2007
NCT00517517 Completed Phase 1/Phase 2 Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived) July 2007 February 2008
NCT00518453 Completed Phase 2 Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Formulation 2007-2008 July 2007 August 2007
NCT00518726 Completed Phase 2 Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to NON Elderly AND Elderly Subjects June 2007 July 2007
NCT00521586 Completed Phase 3 Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine September 2007 December 2013
NCT00522236 Completed Phase 2 Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to Elderly Subjects June 2007 July 2007
NCT00524940 Completed Phase 2 Trial to Describe the Safety and Immunogenicity of Fluzone® August 2007 December 2007
NCT00527865 Completed Phase 1 Single Dose Escalating Study of DAS181 in Adults October 2007 January 2009
NCT00529516 Completed Phase 3 Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults October 15, 2007 June 4, 2008
NCT00530660 Completed Phase 2 Safety and Immunogenicity Study of a Booster Vaccination With a Non-Adjuvanted H5N1 Influenza Vaccine (Follow Up to Study 810501) September 2007 October 2008
NCT00531700 Completed N/A Testing a Personally Controlled Health Record to Ameliorate Influenza at MIT October 2007 January 2009
NCT00532298 Completed Phase 2 Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and Over September 20, 2007 November 2, 2007
NCT00538213 Completed Phase 2 Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults October 15, 2007 November 28, 2007
NCT00538473 Completed Phase 2 Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults October 23, 2007 December 12, 2007
NCT00538512 Completed Phase 4 Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4 September 2007 May 2008
NCT00539864 Completed Phase 3 Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV September 2007 April 2008
NCT00539981 Completed Phase 3 Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok September 15, 2007 May 28, 2008
NCT00540228 Completed Phase 2 Study to Evaluate an Influenza Vaccine Candidate October 5, 2007 May 8, 2008
NCT00540592 Completed Phase 2 Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A October 8, 2007 June 10, 2008
NCT00545025 Completed Phase 2 Revaccination With Influenza Vaccine GSK1247446A October 15, 2007 December 12, 2007
NCT00545701 Completed Phase 2 Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults October 2007 September 2008
NCT00546585 Completed Phase 1/Phase 2 Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults March 2008 February 2009
NCT00551031 Completed Phase 2 Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects October 2007 November 2008
NCT00554333 Completed Phase 3 Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM Vaccine October 2007 December 2007
NCT00555893 Completed N/A Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing Influenza January 2008 February 2011
NCT00556062 Completed Phase 4 Phase IV Clinical Trial of an Influenza Split Vaccine Anflu September 2007 November 2007
NCT00561002 Completed Phase 4 Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® Vaccine October 2007 June 2008
NCT00562484 Completed Phase 4 A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults March 2008 January 2010
NCT00566345 Completed Phase 3 Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII) November 2007 June 2008
NCT00570037 Completed N/A Feasibility of Cocooning Immunization Strategy With Influenza Vaccine October 2007 April 2008
NCT00579345 Completed Phase 3 Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup October 2007 June 2008
NCT00593502 Completed Phase 4 Early Oseltamivir Treatment of Influenza in Children 1-3 Years of Age February 2008 June 2009
NCT00593970 Completed Influenza Vaccine in Pregnancy Part 2 November 2007 October 2013
NCT00606359 Completed Phase 2 Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects November 2007 June 2008
NCT00616928 Completed Phase 3 Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years January 23, 2008 March 19, 2009
NCT00617318 Completed Phase 3 Pomegranate Products for Prevention of Common Cold January 2007 June 2007
NCT00617331 Completed Phase 2 H9 Priming Study in Healthy Adults February 2008 January 2009
NCT00617851 Completed Phase 3 Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years Old November 2007 June 2008
NCT00620815 Completed Phase 2 Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above November 2007 December 2008
NCT00623181 Completed Phase 2 Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy Adults January 2008 June 2008
NCT00630331 Completed Phase 3 Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects October 2007 July 2008
NCT00633074 Completed Phase 2 Non-inferiority Study of GSK Biologicals' Influenza Vaccine GSK576389A Using Different Formulations March 3, 2008 April 11, 2008
NCT00636662 Completed FLU A+B Nasal Swab Clinical Study February 2008 May 2008
NCT00645411 Completed Phase 2/Phase 3 Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents October 2007 July 2008
NCT00646152 Completed Phase 1 Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study March 24, 2008 December 16, 2009
NCT00649883 Completed Phase 2 Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months January 2008 October 2008
NCT00652743 Completed Phase 3 Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules March 23, 2008 June 8, 2011
NCT00657111 Completed Phase 1 CS-8958 Single Inhaled Dose in Elderly April 2008 October 2009
NCT00662272 Completed Phase 1 Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant June 2008 December 2009
NCT00664417 Completed Phase 1 Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine April 2008 August 2010
NCT00665509 Completed Phase 3 Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 08/09 Season. June 2008 July 2008
NCT00677820 Completed Phase 4 A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine June 2008 December 2008
NCT00680069 Completed Phase 1/Phase 2 H5N1 (Clade 2) Vaccination of Adults and Elderly November 2008 November 2009
NCT00693706 Completed Phase 1 Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix June 2, 2008 March 26, 2009
NCT00694213 Completed Phase 1 Pandemic Influenza Plasmid DNA Vaccines (Needle-Free) August 2007 February 2011
NCT00695669 Completed Phase 2 A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64 June 5, 2008 January 8, 2009
NCT00700193 Completed Phase 3 A Study of the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric Population March 2005
NCT00703053 Completed Phase 2 H5N1 Priming and Boosting Strategies September 2008 November 2009
NCT00703651 Completed Phase 2 Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults September 2003 July 2006
NCT00706563 Completed Phase 3 A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ / Influsplit SSW® 2008/2009 in Adults July 7, 2008 July 30, 2008
NCT00706732 Completed Phase 1/Phase 2 A Safety and Immunogenicity Trial in Adults 65 Years of Age or Over to Prevent Influenza June 2008 March 2009
NCT00707941 Completed Phase 3 Oseltamivir Randomised Controlled Efficacy Trial May 2008 March 2011
NCT00709800 Completed Phase 1 Pandemic Influenza Plasmid DNA Vaccines (Needle) August 2007
NCT00710866 Completed Phase 3 Influenza Vaccine Dose-Response in Infants and Toddlers: Immunogenicity and Reactogenicity August 2008 March 2009
NCT00711295 Completed Phase 3 Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups August 2008 October 2010
NCT00714285 Completed Phase 1 Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults. July 14, 2008 January 28, 2009
NCT00718146 Completed Phase 2 Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation June 2008 September 2008
NCT00719043 Completed Phase 2 Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years July 11, 2008 February 18, 2011
NCT00722774 Completed Phase 1 Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine
NCT00727428 Completed Phase 1 Immunogenicity and Safety of GSK Biologicals' FluLaval® TF August 5, 2008 February 17, 2009
NCT00730457 Completed Phase 1 Phase 1 Safety and Immunogenicity Study in Healthy Adults of VAX125, a Recombinant HA-flagellin Influenza Vaccine July 2008 June 2009
NCT00731029 Completed Phase 3 Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002/03 v/s Std Formulation of Influsplit SSW® 2002/03 September 2002
NCT00731393 Completed Phase 3 Immuno & Reacto of TF Trivalent Influenza Split Vaccine 2003/04 or of Std Formulation Influsplit SSW®/Fluarix™ 2003/04 October 2003 August 2004
NCT00734175 Completed Phase 1 Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine September 2008
NCT00735020 Completed Phase 1 Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza Vaccines June 2008 August 2008
NCT00735475 Completed Phase 4 A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine October 2008 June 2009
NCT00741806 Completed Phase 1 Dose-escalation Study of Single Dose GHB04L1 in Healthy Adults August 2008 March 2010
NCT00742885 Completed Phase 2 Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine September 1, 2008 March 7, 2009
NCT00743275 Completed Phase 4 A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination August 2008 November 2008
NCT00748150 Completed Phase 2 Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009, When Administered to Non-Elderly Adult and Elderly Subjects July 2008 August 2008
NCT00750360 Completed Phase 4 Study to Monitor the Safety and Reactogenicity of Fluarix™ in Korean Subjects Aged > 6 Months of Age. October 3, 2003 December 28, 2007
NCT00753272 Completed Phase 3 Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older September 15, 2008 January 5, 2011
NCT00754455 Completed Phase 2 Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy Adults September 2008 March 2009
NCT00755274 Completed Phase 4 Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone® September 2008 January 2009
NCT00756574 Completed N/A Randomized Control Trial to Study the Efficacy of the Surgical Mask Versus the N95 Respirator to Prevent Influenza October 2008 May 2009
NCT00757900 Completed Phase 4 Efficacy of Influenza Vaccine in HIV Infected Adults April 2008 September 2008
NCT00760617 Completed Phase 3 Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older October 6, 2008 May 15, 2009
NCT00764790 Completed Phase 3 Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children October 1, 2008 June 1, 2009
NCT00764998 Completed Phase 3 Influenza Vaccine in HIV October 2008 August 2009
NCT00765076 Completed Phase 3 Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older October 16, 2008 December 4, 2009
NCT00771615 Completed Phase 2 Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years October 16, 2008 December 4, 2009
NCT00772109 Completed Phase 3 Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults October 2008 July 2009
NCT00772889 Completed Phase 3 Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly October 9, 2008 December 15, 2009
NCT00775450 Completed Phase 2 Influenza Vaccine Revaccination in Ambulatory Elderly Subjects October 2008 July 2009
NCT00776438 Completed Phase 2 Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines September 2007 April 2009
NCT00778297 Completed N/A Immunogenicity and Tolerability Study of FluvalAB FL-K-004 Trivalent Influenza Vaccine November 2007 May 2008
NCT00778895 Completed Phase 2 Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control November 10, 2008 August 19, 2009
NCT00782431 Completed Phase 3 Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older November 2008 July 2009
NCT00783926 Completed Phase 1 Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant) July 2008 July 2009
NCT00784784 Completed Phase 3 Zanamivir Versus Trivalent Split Virus Influenza Vaccine November 2008 June 2009
NCT00798343 Completed Phase 1 Heterosubtypic Immune Responses to Influenza in Older People January 2009 September 2013
NCT00800605 Completed Phase 3 Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection December 2008 June 2009
NCT00812019 Completed Phase 1 Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old) November 2008 November 2010
NCT00812110 Completed Phase 4 Influenza Vaccination for Parents and Other Caregivers in the Pediatric Medical Home December 2008 September 2009
NCT00812981 Completed Phase 3 A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine. November 15, 2008 June 7, 2009
NCT00814229 Completed Phase 1 Safety and Immunogenicity of Influenza H9 Vaccine in Humans August 2007 September 2008
NCT00814385 Completed Phase 1/Phase 2 Immunogenicity of Adjuvanted or Non-adjuvanted H5N1 Booster Vaccine in Adults Primed to A/VN/1194/04 November 2008 December 2013
NCT00817661 Completed N/A Vitamin A and Maternal-infant Flu Vaccine Response February 2009 July 2010
NCT00819013 Completed Phase 1 Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults July 2007 February 2009
NCT00821626 Completed N/A Rapid Flu Tests in Travelers With Fever January 2009 May 2015
NCT00822627 Completed N/A Influenza Vaccination in the Emergency Department November 2007 April 2008
NCT00825162 Completed Phase 4 Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 Years March 2009 February 2010
NCT00831675 Completed Phase 4 Study of Safety and Immunogenicity of Fluzone® in Healthy Children September 2004 April 2006
NCT00831987 Completed Phase 4 Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine August 2004 February 2006
NCT00833885 Completed N/A Tolerability and Measurability of the Efficacy of Non Pharmaceutical Measures to Prevent Seasonal Influenza January 2009 April 2011
NCT00835926 Completed Phase 4 A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination July 2003 September 2003
NCT00836953 Completed Phase 4 Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone® September 2003 July 2004
NCT00844051 Completed N/A Study to Evaluate Impact of School-based Influenza Vaccination on School Populations January 2009 June 2011
NCT00845429 Completed Phase 2 Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects October 2007 November 2008
NCT00848848 Completed Phase 1 Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older October 2008 April 2009
NCT00848887 Completed Phase 1 A Dose Ranging Study Comparing Different Combinations of Adjuvanted and Non-adjuvanted Influenza Vaccines in Healthy Children 6 to <36 Months of Age October 2008 May 2009
NCT00851266 Completed Phase 1 A Study of a Bivalent Influenza Peptide Conjugate Vaccine in Healthy Adults October 2006 January 2009
NCT00853255 Completed Phase 1 Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy Adults July 2010 December 2011
NCT00858468 Completed Phase 1/Phase 2 Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age April 2005 December 2006
NCT00867139 Completed Phase 1/Phase 2 TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients March 2009 January 2010
NCT00868218 Completed Phase 1 Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults March 2009 November 2013
NCT00877396 Completed Phase 4 Hutterite Influenza Prevention Study September 2008 July 2011
NCT00881842 Completed Phase 3 Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 09/10 Season June 2009 July 2009
NCT00884117 Completed Influenza Resistance Information Study January 2009 November 2015
NCT00884182 Completed Phase 2 Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children April 2009 June 2010
NCT00885105 Completed Phase 3 Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age October 2005 September 2007
NCT00888381 Completed Phase 4 A Study to Assess the Immunogenicity and Safety of CSL's 2009 / 2010 Formulation of Enzira® Vaccine in Healthy Volunteers May 2009 May 2009
NCT00889889 Completed Phase 2 Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Adults Aged >= 18 and <= 64, Plus Revaccination May 2009 January 2011
NCT00893906 Completed Phase 4 Inactivated Influenza Vaccine Effectiveness in Tropical Africa May 2009 April 2013
NCT00895544 Completed Phase 1/Phase 2 Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in Adults May 2009 June 2011
NCT00900588 Completed Phase 2 Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescents
NCT00900991 Completed Phase 2 Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Children
NCT00905125 Completed Phase 2 Influenza Vaccine in Pregnant Women June 2009 March 2010
NCT00912496 Completed Phase 1 Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59 June 2010 December 2011
NCT00915187 Completed Phase 2 Safety and Immunogenicity Study of Intramuscular CCS/C-adjuvanted Influenza Vaccine in Elderly October 2009 February 2010
NCT00920374 Completed Phase 3 A Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in Adults June 16, 2009 July 8, 2009
NCT00921206 Completed Phase 1 Study to Investigate the Immune Response to Two Doses of VAX102 Healthy Adults June 2009 December 2009
NCT00921726 Completed Phase 1 Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults July 2009 October 2009
NCT00921947 Completed Phase 1/Phase 2 Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults June 2009 August 2009
NCT00921973 Completed Phase 1 Safety of VAX102 Vaccine Given With Seasonal Flu Vaccine in Healthy Adults June 2009 September 2009
NCT00934245 Completed Phase 4 Direct and Indirect Protection by Influenza Vaccine Given to Children in India September 2009 July 2012
NCT00935194 Completed Phase 4 Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) : Multi-centre, Prospective, Randomized Controlled Study July 2009 November 2009
NCT00936468 Completed Phase 2 Safety, Tolerability and Immunogenicity of Fluzone® With and Without JVRS-100 in Elderly Subjects September 2009 September 2010
NCT00938392 Completed Phase 3 Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly July 30, 2009 October 5, 2009
NCT00942071 Completed Phase 1 A Study to Assess the Safety and Immunogenicity of a New Influenza Vaccine Candidate MVA-NP+M1 in Healthy Adults August 2008 November 2012
NCT00943202 Completed Phase 2 Sanofi Pasteur, TIV + H1N1, Pediatric Population August 2009 May 2010
NCT00943358 Completed Phase 1 Safety and Immunogenicity of A/H1N1v Vaccines in Healthy Adults July 2009 December 2009
NCT00943488 Completed Phase 2 CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations August 2009 March 2010
NCT00943631 Completed Phase 2 Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations August 2009 March 2010
NCT00943657 Completed Phase 3 Yearly Strain Variation Study, 2009/2010 June 2009 July 2009
NCT00943878 Completed Phase 2 Sanofi H1N1 + TIV - Adults and Elderly August 2009 April 2010
NCT00944073 Completed Phase 2 Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels August 2009 April 2010
NCT00945438 Completed Phase 2 Study of the Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation (Intradermal Route) May 2009 July 2009
NCT00946101 Completed Phase 4 A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age August 2009 March 2010
NCT00946179 Completed Phase 2 Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation May 2009 July 2009
NCT00949533 Completed Phase 3 A Study on Emergence of Resistance With Oseltamivir (Tamiflu) in Participants With Seasonal Influenza August 2009 October 2010
NCT00950456 Completed Observational Study to Assess Safety of H1N1 Pandemic Influenza Vaccine November 2009 February 2011
NCT00951041 Completed Phase 2 Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults August 11, 2009 August 30, 2010
NCT00952276 Completed Phase 2 A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly October 2009 March 2011
NCT00952419 Completed Phase 2 A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years August 2009 June 2010
NCT00953524 Completed Phase 2 A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly August 2009 December 2010
NCT00954798 Completed Phase 2 A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the Elderly August 2009 March 2011
NCT00956046 Completed Phase 2 A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months September 2009 June 2011
NCT00956111 Completed Phase 4 A Clinical Trial With Influenza A/H1N1 Vaccines July 2009 October 2009
NCT00956202 Completed Phase 2 A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years August 2009 November 2010
NCT00956449 Completed Phase 2 Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects June 2009 July 2009
NCT00958126 Completed Phase 2 A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA August 2009 April 2010
NCT00958243 Completed Phase 2 A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA August 2009 April 2010
NCT00959049 Completed Phase 3 A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population September 2009 May 2010
NCT00959465 Completed Phase 1/Phase 2 A/H1N1 Immunogenicity and Safety in Adults August 2009 April 2010
NCT00961337 Completed Phase 4 Evaluation of a School-based Influenza Vaccination Program October 2008 May 2009
NCT00963157 Completed Phase 2 Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations September 2009 December 2010
NCT00963430 Completed Phase 2 H1N1 Vaccine in Pregnant Women September 2009 May 2010
NCT00964158 Completed Phase 3 Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A) September 10, 2009 November 27, 2010
NCT00965354 Completed Mechanisms of Severe Acute Influenza Consortium (MOSAIC) December 2009 February 2011
NCT00966238 Completed Phase 2 Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults >= 65 Years of Age September 2009 March 2011
NCT00968526 Completed Phase 3 Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults September 8, 2009 September 23, 2010
NCT00968539 Completed Phase 3 Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults September 8, 2009 September 28, 2010
NCT00968890 Completed Phase 2 Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in Elderly September 12, 2009 September 23, 2010
NCT00971321 Completed Phase 2 Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A) September 10, 2009 November 24, 2010
NCT00971425 Completed Phase 3 Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) September 8, 2009 October 8, 2010
NCT00972517 Completed Phase 3 Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children September 29, 2009 November 22, 2010
NCT00972816 Completed Phase 2/Phase 3 Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years) September 2009 October 2010
NCT00973349 Completed Phase 2/Phase 3 Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults September 2009 December 2010
NCT00975572 Completed Phase 2 Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Population Aged 3 Years and Older July 2009 February 2010
NCT00975884 Completed Phase 3 Study to Evaluate Immunogenicity & Safety of an Investigational Influenza Vaccine in Adults September 14, 2009 April 30, 2010
NCT03143101 Completed Phase 4 Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age May 8, 2017 September 29, 2017
NCT00006146 Completed Phase 2 Half-Dose Flu Vaccine Study in Healthy Adults August 2000 September 2000
NCT00091702 Completed Phase 1/Phase 2 Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents January 2006
NCT00100399 Completed Phase 3 Fluarix Immunogenicity and Safety Trial December 2004 December 2004
NCT00110279 Completed Phase 1 Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A) June 2005 September 2005
NCT00111579 Completed Phase 2 Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV) May 2005 January 2006
NCT00115531 Completed Phase 2 Eldery High Dose TIV 2005 April 2005 November 2005
NCT00115986 Completed Phase 1/Phase 2 A/H5N1in Adult - Aventis March 2005 February 2006
NCT00125944 Completed Phase 3 Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults July 2005 January 2006
NCT00128167 Completed Phase 3 Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age October 2004 December 2005
NCT00133471 Completed Phase 1/Phase 2 Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults March 2005 December 2005
NCT00133510 Completed Phase 4 Influenza Vaccine in Pediatric Transplant Subjects November 2004 September 2006
NCT00133523 Completed Phase 4 FLU-VACS Comparative Study in Adults October 2004 July 2007
NCT00133536 Completed Phase 1/Phase 2 A/H5N1 Vaccine in Healthy Children Aged 2-9 Years January 2006 April 2007
NCT00133588 Completed Phase 4 Proteomic Profiling for Influenza November 2006 January 2007
NCT00136331 Completed Phase 1 Study of a Pandemic Influenza Vaccine October 2005 November 2006
NCT00137579 Completed Phase 4 Safety of the Intramuscular Route of the Anti-Flu Vaccine in Patients Receiving Oral Anticoagulation Therapy September 2003 May 2004
NCT00138281 Completed Phase 4 Influenza Immunity Against Pandemic Respiratory Virus January 2006
NCT00138294 Completed Phase 4 Control of Epidemic Influenza Through a School-based Influenza Vaccination Program October 1998 June 2010
NCT00138385 Completed Phase 4 Comparison of Inactivated and Live, Attenuated Influenza Vaccine in Children 5-9 Years of Age-Year 3 Amendment August 2005 June 2007
NCT00138398 Completed N/A T-cell Response-Flu Risk in Older Adults October 25, 2005
NCT00142077 Completed N/A Electronic Health Records for Health Promotion October 2005 May 2006
NCT00158665 Completed N/A A Comparison of One Versus Two Doses of Influenza Vaccine in Children 5-8 Years of Age August 2004 December 2004
NCT00161811 Completed Phase 2/Phase 3 Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2004/2005 November 2004 July 2005
NCT03023176 Completed Phase 4 T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 5, 2013 September 2013 November 2013
NCT03023553 Completed Phase 4 The Human Mucosal Immune Responses to Influenza Virus (SLVP026) December 2012 February 2013
NCT03023683 Completed Phase 4 Protective Mechanisms Against a Pandemic Respiratory Virus (SLVP024) October 2012 November 2012
NCT03028974 Completed Phase 4 Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029) September 17, 2014 November 20, 2017
NCT03035396 Completed N/A Clinical Performance of the Diassess Influenza A and B Test December 29, 2016 May 2017
NCT03058692 Completed Phase 2 Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine April 9, 2018 January 14, 2019
NCT03061955 Completed Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab) October 1, 2016 April 26, 2019
NCT03068949 Completed Phase 4 Comparison of Three Licensed Influenza Vaccines October 28, 2015 June 30, 2021
NCT03076385 Completed Phase 1 Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects December 2015 October 2018
NCT03088904 Completed Phase 1 Genetic and Environmental Factors in the Response to Influenza Vaccination October 3, 2014 December 12, 2018
NCT03101462 Completed Phase 4 Live Attenuated Influenza Vaccine (LAIV) Versus Trivalent Inactivated Influenza Vaccine in Healthy Adults 18-49 Years February 24, 2011 November 9, 2011
NCT03104790 Completed Phase 4 Assessment of Viral Shedding in Children Previously in Receipt of Multiple Doses of Live Attenuated Influenza Vaccine (LAIV) Compared to Influenza Vaccine-naïve Controls October 2, 2017 March 13, 2018
NCT03139565 Completed Phase 3 High Dose vs. Standard Influenza Vaccine in Adult SOT October 2016 July 2020
NCT00001127 Completed Phase 3 Study of a Flu Vaccine in Children November 2005
NCT03158038 Completed Phase 4 Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season May 30, 2017 December 14, 2017
NCT03163342 Completed Phase 4 Immune Response Following Seasonal Influenza Vaccination May 8, 2017 June 15, 2018
NCT03180801 Completed Phase 2 Efficacy of FLU-v in an H1N1 Influenza Human Challenge Model August 18, 2016 May 25, 2017
NCT03186781 Completed Phase 1 Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults October 25, 2017 September 3, 2019
NCT03231995 Completed N/A Biomarkers for the Prognosis of Influenza in Children January 15, 2019 April 20, 2022
NCT03232567 Completed Phase 2 Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX September 18, 2017 June 15, 2018
NCT03233217 Completed Phase 1/Phase 2 Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years September 15, 2017 November 28, 2017
NCT03239665 Completed N/A Vaccination Education Through Pharmacists and Senior Centers (VEPSC) October 10, 2017 August 31, 2019
NCT03248960 Completed N/A Ellume.Lab Flu A+B Test and iTreat Flu A+B Flu Test Performance Versus Viral Culture and Reverse Transcriptase Polymerase Chain Reaction. July 27, 2017 December 23, 2017
NCT03266237 Completed Phase 4 The Immune Response to Influenza Vaccinations in Elderly Individuals December 2013 May 2016
NCT03274310 Completed N/A FluSAFE: Flu SMS Alerts to Freeze Exposure October 6, 2017 May 15, 2021
NCT03282240 Completed Phase 3 Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US September 8, 2017 April 19, 2018
NCT03287830 Completed N/A Flu2Text: Text Message Reminders for 2nd Dose of Influenza Vaccine October 6, 2017 April 30, 2019
NCT03293498 Completed Phase 1/Phase 2 Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu) September 18, 2017 October 29, 2018
NCT03300050 Completed Phase 1 Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine October 10, 2017 August 9, 2019
NCT03301051 Completed Phase 3 Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults August 31, 2017 May 9, 2018
NCT03308825 Completed Phase 4 Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines September 11, 2017 November 22, 2017
NCT03312699 Completed Phase 1 Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort September 19, 2017 December 31, 2023
NCT03318315 Completed Phase 2 Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4 February 20, 2018 July 25, 2019
NCT03321968 Completed Phase 3 Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults September 29, 2017 December 1, 2017
NCT03328325 Completed Phase 4 Age and Response to Flu Vaccines December 14, 2017 April 20, 2020
NCT03330899 Completed Phase 1 Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil September 24, 2018 August 25, 2020
NCT03336619 Completed Phase 3 A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza January 17, 2018 April 17, 2019
NCT03344029 Completed Phase 4 Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years November 3, 2017 May 22, 2018
NCT03345043 Completed Phase 1 Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects May 11, 2016 August 13, 2018
NCT03372967 Completed Project IMPACT Immunizations (IMProving America's Communities Together) Scaled Demonstration December 12, 2017 November 20, 2019
NCT03390166 Completed Phase 2/Phase 3 Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults July 24, 2017 February 12, 2019
NCT03391193 Completed Phase 3 Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine December 19, 2017 August 25, 2018
NCT03394209 Completed Phase 2 A Pharmacokinetics Study of Favipiravir in Patients With Severe Influenza February 6, 2018 March 27, 2019
NCT03430089 Completed Phase 1 Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine February 22, 2019 June 6, 2019
NCT03437304 Completed Phase 1/Phase 2 Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU in Older Adults February 9, 2018 November 30, 2018
NCT03441373 Completed Phase 2/Phase 3 XC8 in the Treatment of Patients With Acute Respiratory Viral Infection February 3, 2016 February 9, 2017
NCT03450915 Completed Phase 3 A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine August 1, 2018 October 23, 2020
NCT03451656 Completed Prospective System Analysis of the Seasonal Influenza Virus Transmissions and Evolution in the City of Basel Basel December 27, 2016 April 30, 2017
NCT03453801 Completed Phase 1 The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection September 30, 2014 January 14, 2019
NCT03455491 Completed Phase 2 Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections February 12, 2018 June 28, 2018
NCT03459391 Completed Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers May 22, 2017 September 26, 2017
NCT03474887 Completed Digital Online Consultations - Effects on Antibiotic Prescribing and Health Care Utilization in Primary Care March 30, 2018 December 20, 2021
NCT03481270 Completed N/A The Oakland Men's Health Disparities Study October 14, 2017 March 3, 2018
NCT03546192 Completed Phase 4 Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route) June 17, 2015 July 17, 2015
NCT03553940 Completed Phase 1 H3N2 M2SR in Pediatric Population August 15, 2018 August 27, 2020
NCT03564444 Completed Phase 4 D2560C00015 FluMist Annual Safety Study 2018 June 6, 2018 December 27, 2018
NCT03581903 Completed Phase 1 A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine September 19, 2017 February 6, 2019
NCT03590808 Completed N/A Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor September 1, 2018 May 30, 2019
NCT03594890 Completed Phase 1 Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects June 12, 2018 August 7, 2019
NCT03595358 Completed N/A Ellume·Lab Flu A+B Test and the Ellume Home Flu Test Performance Versus Viral Culture and Reverse Transcriptase Polymerase Chain Reaction August 31, 2018 November 16, 2018
NCT03599739 Completed Adjuvanted Influenza Vaccination Year 2 Follow-On Survey July 13, 2018 January 25, 2023
NCT03600428 Completed Phase 4 Safety of LAIV4 in Children With Asthma October 15, 2018 March 20, 2020
NCT03603509 Completed Phase 4 Gene Signatures of Influenza Vaccine Responses in Older Adults August 27, 2018 January 2, 2019
NCT03617523 Completed Phase 4 Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations September 10, 2018 November 12, 2018
NCT03629184 Completed Phase 3 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms November 20, 2018 April 3, 2019
NCT03653364 Completed Phase 3 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms January 23, 2019 April 3, 2023
NCT03666026 Completed N/A Patient Portal - Flu Reminder Recall October 2, 2018 April 2, 2019
NCT03669627 Completed Phase 2 CT18 Infant Influenza Priming Study in Vaccine Naive Infants November 1, 2018 July 21, 2021
NCT03673345 Completed Phase 4 Development of Childhood Anti-Influenza Immunity September 25, 2018 December 22, 2020
NCT03679143 Completed Phase 1 The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers. September 20, 2018 April 26, 2019
NCT03684044 Completed Phase 3 Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza January 8, 2019 March 16, 2020
NCT03694392 Completed Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years September 16, 2018 December 31, 2022
NCT03698279 Completed Phase 2 Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age October 9, 2018 October 16, 2019
NCT03699839 Completed Phase 2/Phase 3 Reducing the Burden of Influenza After Solid-Organ Transplantation October 26, 2018 August 15, 2020
NCT03704740 Completed Phase 3 Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months October 25, 2018 July 12, 2019
NCT03718468 Completed Phase 3 A Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine October 30, 2018 July 3, 2019
NCT03722589 Completed Phase 4 Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP September 12, 2018 July 31, 2020
NCT03743688 Completed Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults December 4, 2018 July 26, 2019
NCT03744104 Completed Phase 3 A Clinical Trial of A Quadrivalent Influenza Vaccine October 11, 2018 October 8, 2019
NCT03757546 Completed Extra-pulmonary Clinical Manifestations of Influenza Virus and Respiratory Syncitial Virus Infections December 3, 2018 April 14, 2019
NCT03760549 Completed Study of the Safety and Immunogenicity of NasoVAX Extension January 21, 2019 February 18, 2019
NCT03765437 Completed Phase 3 Safety of a Quadrivalent Influenza Vaccine (VaxigripTetra™) in Subjects Aged 6 Months and Older in Vietnam January 15, 2019 March 17, 2019
NCT03777163 Completed Phase 4 Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine April 22, 2019 March 30, 2020
NCT03816878 Completed Phase 1 Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals January 8, 2019 March 17, 2020
NCT03826719 Completed Phase 1/Phase 2 Safety, Tolerability and Immunogenicity of NBP607QIV in Healthy Adult Volunteers February 17, 2014 March 28, 2014
NCT03830905 Completed Phase 2 Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI January 31, 2019 July 3, 2019
NCT03845231 Completed Phase 2 Mucosal and Systemic Immunity After Viral Challenge of Healthy Volunteers Vaccinated With Inactivated Influenza Vaccine Via the Intranasal Versus Intramuscular Route April 29, 2019 October 28, 2020
NCT03849560 Completed Phase 2/Phase 3 Safety, Reactogenicity, Immunogenicity, and Efficacy of Quadrivalent Inactivated Subunit Influenza Vaccine Grippol® Quadri and Trivalent Inactivated Polymer-Subunit Vaccine Grippol® Plus in Volunteers November 2016 August 2017
NCT03883113 Completed Phase 2 Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model June 3, 2019 April 17, 2020
NCT03888989 Completed Phase 1 Response to Influenza Vaccine During Pregnancy September 30, 2019 December 31, 2023
NCT03898986 Completed Phase 1 The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin Sets October 8, 2019 December 31, 2023
NCT03926416 Completed Phase 1 Safety Study of Live Attenuated Influenza Vaccine, CodaVax February 21, 2017 September 14, 2018
NCT03930017 Completed Pregnancy, Arsenic and Immune Response October 14, 2018 January 6, 2020
NCT03945825 Completed Phase 1 Flublok or Fluzone With Advax-CpG55.2 or AF03 June 10, 2019 September 18, 2020
NCT03950986 Completed N/A Increasing Vaccine Uptake Among Veterans at the Atlanta VA Health Care System October 15, 2018 June 30, 2019
NCT03969212 Completed Phase 3 Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households October 10, 2019 May 10, 2024
NCT04044352 Completed Phase 1 H1N1v Virus Challenge Study in Healthy Subjects October 22, 2019 March 2, 2020
NCT04074928 Completed Phase 3 Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects September 6, 2019 September 3, 2020
NCT04091880 Completed Phase 4 Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine September 26, 2019 August 10, 2021
NCT04101435 Completed Phase 3 Immunogenicity and Safety Evaluation of QIS in Healthy Subjects December 28, 2016 December 27, 2017
NCT04106817 Completed Phase 1 Single Ascending Dose Challenge Study to Determine Safety and Reactogenicity of an Influenza Challenge Virus January 19, 2015 August 10, 2015
NCT04109222 Completed Phase 4 Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively September 30, 2019 December 10, 2019
NCT04110314 Completed N/A Patient Portal Reminder/Recall for Influenza Vaccination in a Health System- RCT 2 October 18, 2019 April 1, 2020
NCT04110366 Completed N/A Nasal and Systemic Immune Responses to Nasal Influenza Vaccine June 14, 2018 May 29, 2020
NCT04141930 Completed Phase 4 Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle November 1, 2019 April 1, 2020
NCT04144179 Completed Phase 1 Recombinant Influenza Vaccine Containing Different H3 Antigens in Healthy Adults 18 to 30 Years of Age November 6, 2019 February 24, 2020
NCT04146623 Completed Phase 1 Safety Study of Live Attenuated Influenza Vaccine, CodaVax, Delivered Via Intranasal Spray May 7, 2019 November 11, 2020
NCT04171128 Completed Procalcitonin Role in Influenza Patients With Regard to Morbidity, Mortality and Antibiotic Use February 2, 2019 August 1, 2020
NCT04192500 Completed Phase 2 Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years December 11, 2019 September 7, 2020
NCT04210349 Completed Phase 3 Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age January 9, 2020 December 1, 2020
NCT04232956 Completed Invasive Pulmonary Aspergillosis and Severe Influenza July 27, 2018 November 5, 2018
NCT04239521 Completed The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata October 1, 2020 November 28, 2022
NCT04282135 Completed Detection of Influenza or SARS-CoV-2 Infection by IMS of Nasal Air Sampling February 15, 2020 June 30, 2020
NCT04323137 Completed N/A Encouraging Flu Vaccination Among High-Risk Patients Identified by ML September 21, 2020 September 21, 2021
NCT04326309 Completed Audio Data Collection for Identification and Classification of Coughing March 25, 2020 January 24, 2022
NCT04363359 Completed Phase 2 Clinical Trial of Quadrivalent Influenza Virus Split Vaccine January 15, 2020 September 14, 2021
NCT04365608 Completed N/A Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment March 20, 2020 December 10, 2020
NCT04385420 Completed Phase 1 Phase 1 Study of ATR-002 April 24, 2019 August 26, 2019
NCT04439695 Completed Phase 1 Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults June 25, 2020 July 28, 2021
NCT04460781 Completed Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring September 17, 2018 February 28, 2022
NCT04523324 Completed Phase 4 Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel October 31, 2019 August 30, 2022
NCT04530786 Completed Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies Beyond the Season December 2004 July 2009
NCT04531657 Completed Influenza Vaccine in Lung Transplant Patients - Seroprotection December 2004 July 2009
NCT04531787 Completed Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies August 2004 July 2009
NCT04533061 Completed Influenza Vaccine in Lung Transplant Patients - T Cells December 2004 July 2009
NCT04533139 Completed Influenza Vaccine in Lung Transplant Patients - Antibody December 2004 July 2009
NCT04533685 Completed N/A Patient Portal Reminder/Recall for Influenza Vaccination in a Health System- UCLA Portal R/R Influenza RCT 3 September 1, 2020 April 1, 2021
NCT04570904 Completed Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness September 28, 2020 September 1, 2021
NCT04576702 Completed Phase 2 Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults October 8, 2020 May 24, 2021
NCT04579250 Completed Phase 1 Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults October 8, 2020 January 27, 2022
NCT04579614 Completed N/A Performance Feedback in Health Care September 23, 2019 December 31, 2019
NCT04603989 Completed Phase 1 A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics August 1, 2020 November 13, 2020
NCT04610047 Completed Phase 2 Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness December 14, 2020 February 9, 2022
NCT04611061 Completed Kagocel® for the Prevention of ARVI and Influenza in Adults Health Care Workers October 2, 2017 June 14, 2018
NCT04622592 Completed Phase 1/Phase 2 Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older November 2, 2020 April 26, 2022
NCT04626622 Completed Kagocel® for the Prevention of ARVI and Influenza in Young People February 15, 2018 June 30, 2018
NCT04651491 Completed Treatment of Influenza and ARVI in Children by Kagocel ® September 11, 2015 September 28, 2016
NCT04663776 Completed Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-Based Study Platform November 4, 2020 December 8, 2021
NCT04668417 Completed N/A Pediatric Second Influenza Dose Portal Reminder Recall December 15, 2020 April 1, 2021
NCT04678271 Completed N/A Assessment, Feedback, Incentive, Exchange (AFIX OB) A Customizable Quality Improvement Intervention to Increase Maternal Vaccine Uptake July 1, 2021 January 31, 2023
NCT04695717 Completed Phase 3 This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam September 5, 2020 April 1, 2022
NCT04729764 Completed Phase 1 Evaluation the Safety and Tolerance of GP681 Tablets in Healthy Subjects August 27, 2020 December 15, 2020
NCT04736758 Completed Phase 2 A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza January 8, 2021 December 18, 2021
NCT04782323 Completed Phase 2 Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults April 13, 2021 March 3, 2022
NCT04798677 Completed N/A Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine October 29, 2020 September 24, 2021
NCT04801888 Completed Phase 4 Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine March 23, 2021 May 28, 2021
NCT04896086 Completed Phase 1 First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV, in Healthy Adults May 24, 2021 February 8, 2024
NCT04941092 Completed Comparison of ARDS COVID-19 (WHO) vs ARDS Influenza in the ICU June 1, 2021 July 10, 2021
NCT04978454 Completed Phase 1 Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain August 19, 2021 September 22, 2022
NCT04982913 Completed Phase 1 Single Dose and Multiple Dose Safety, Tolerability, PK，and Food Effect Study，and Interaction With Oseltamivir Study of HEC116094 in Healthy Adult Subjects August 24, 2021 October 2, 2022
NCT05009251 Completed N/A Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake September 9, 2021 July 31, 2022
NCT05012163 Completed N/A Lottery Incentive Nudges to Increase Influenza Vaccinations September 4, 2021 December 31, 2022
NCT05027932 Completed Phase 1 Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine June 27, 2022 March 1, 2024
NCT05030324 Completed Phase 2 A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections October 1, 2021 May 4, 2022
NCT05048589 Completed Phase 2 Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting October 1, 2021 May 31, 2022
NCT05052190 Completed N/A Patient Portal Flu Vaccine Reminders_RCT 4 October 14, 2021 April 1, 2022
NCT05060887 Completed Phase 2 Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers. November 15, 2021 December 7, 2022
NCT05069714 Completed Phase 3 One or Two Week Methotrexate Discontinuation on Efficacy of Influenza Vaccination in Rheumatoid Arthritis. October 1, 2021 September 30, 2022
NCT05082688 Completed Phase 2 Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX) September 20, 2021 May 17, 2023
NCT05087355 Completed Health Status Prior and Post Infection With Influenza or COVID 19: a Population Based Retrospective Analysis of 2016-2021 January 1, 2016 August 31, 2021
NCT05089123 Completed Phase 3 The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old March 3, 2020 August 24, 2020
NCT05095545 Completed Phase 2 Dose Range Study to Evaluate the Efficacy and Safety of AV5080 in Patients With Influenza November 13, 2017 August 30, 2019
NCT05126979 Completed Phase 1 The Objectives of This Study Are Study of the Reactogenicity, Safety and Immunogenicity of Flu-M Inactivated Split Influenza Vaccine in Volunteers Aged 18-60 Years March 9, 2016 May 13, 2016
NCT05152017 Completed Phase 1 The Objectives of This Study Are Study the Safety, Reactogenicity and Obtain Preliminary Data on the Immunogenicity of Flu-M Quadro, 4-valent Inactivated Split Influenza Vaccine, in Healthy Volunteers November 16, 2019 January 24, 2020
NCT05184387 Completed A Prospective Epidemiological Cohort Study Evaluating Occurrences of Influenza-like Illness. December 1, 2021 July 12, 2022
NCT05212623 Completed Phase 1 A Clinical Trial of an Quadrivalent Inactivated Influenza Vaccine in Healthy Children Aged 6 to 35 Months October 26, 2021 June 16, 2022
NCT05252338 Completed Phase 1 A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy Adults February 7, 2022 September 27, 2022
NCT05284799 Completed Phase 2 Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers. May 9, 2022 December 9, 2022
NCT05290792 Completed N/A Use of Wearable Sensors for Early Detection and Tracking of Viral Respiratory Tract Infections December 10, 2021 October 31, 2022
NCT05297994 Completed Phase 2 Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA October 24, 2016 March 9, 2017
NCT05308212 Completed Phase 2/Phase 3 Tolerability, Safety and Immunogenicity Trial of the FLU-M® Tetra March 4, 2021 September 6, 2021
NCT05312294 Completed Phase 3 Tolerability, Safety and Immunogenicity Trial of the Flu-M® Inactivated Vaccine in Volunteers Aged 18 to 60 Years December 7, 2020 November 15, 2021
NCT05313893 Completed Phase 4 A Clinical Trial of an Inactivated Quadrivalent Influenza Vaccine in Chinese Children Aged 3 to 8 Years September 11, 2021 May 30, 2022
NCT05317767 Completed Phase 3 The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years. February 10, 2020 September 14, 2020
NCT05353725 Completed Extracorporeal Membrane Oxygenation in Coronavirus Disease (COVID-19), Influenza and ARDS of Other Ethiologies January 1, 2016 March 1, 2022
NCT05375838 Completed Phase 1/Phase 2 A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old May 13, 2022 December 29, 2022
NCT05406180 Completed Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and Above October 10, 2018 December 27, 2019
NCT05474755 Completed Phase 3 To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection July 28, 2022 October 31, 2023
NCT05492786 Completed N/A High-risk Influenza Vaccine Alert September 1, 2022 April 1, 2023
NCT05493787 Completed N/A Nudging Flu Vaccination by Making it Easy for Patients to Schedule a Flu Shot November 8, 2022 January 3, 2023
NCT05508698 Completed N/A Flu Shot Pre-visit Questionnaire August 18, 2022 April 8, 2023
NCT05509283 Completed N/A Nudging Flu Vaccination in Patients at Moderately High Risk for Flu and Flu-related Complications September 13, 2022 October 26, 2022
NCT05519839 Completed Phase 2 A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine December 30, 2022 December 24, 2023
NCT05523089 Completed Phase 2 The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults September 9, 2022 July 17, 2023
NCT05525494 Completed N/A Patient Portal Flu Vaccine Reminders (5) September 7, 2022 April 1, 2023
NCT05535777 Completed N/A Patient Portal Flu Vaccine Reminders_RCT 5 (LADHS) September 13, 2022 March 31, 2023
NCT05537441 Completed N/A Precision Vaccine Promotion in Underserved Populations September 22, 2022 June 1, 2023
NCT05542004 Completed N/A Nationwide Utilization of Danish Government Electronic Letter System for Increasing InFLUenza Vaccine Uptake September 16, 2022 May 31, 2023
NCT05544916 Completed Phase 3 A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections August 5, 2022 May 4, 2023
NCT05558462 Completed N/A Pharmacokinetics and Bioequivalence of XC8 10 mg and 40 mg Tablets in Fasted Volunteers August 22, 2022 December 7, 2022
NCT05581407 Completed Phase 1 Safety, Tolerability, and Immunogenicity of TETRALITE, a Novel Adjuvanted, Low-dose Influenza Vaccin October 3, 2022 October 23, 2023
NCT05585632 Completed Phase 1 A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old October 14, 2022 February 28, 2024
NCT05608005 Completed Phase 1/Phase 2 Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older November 3, 2022 February 13, 2024
NCT05645900 Completed Phase 3 A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months February 6, 2023 October 13, 2023
NCT05661890 Completed Seasonal Influenza and Pneumococcal Vaccination in the Elderly November 15, 2022 February 15, 2023
NCT05674370 Completed N/A A Study of the GRIP Influenza and SARS-CoV-2 POC Assays February 1, 2023 April 30, 2023
NCT05734040 Completed Phase 2 Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects. May 10, 2023 January 15, 2024
NCT05781191 Completed Analysis of the Determinants of Adherence to Coadministration of Flu Vaccination With the Booster of COVID-19 Vaccine November 13, 2021 December 31, 2021
NCT05832333 Completed Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months October 5, 2019 February 7, 2022
NCT05868382 Completed Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults May 15, 2023 December 19, 2023
NCT05869201 Completed Phase 2/Phase 3 Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine October 6, 2020 December 8, 2020
NCT06020118 Completed Phase 4 Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations September 25, 2023 May 17, 2024
NCT06052527 Completed Covid-19, Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) and Influenza Treatment System With Machine Learning June 16, 2023 October 1, 2023
NCT06077045 Completed Uptake of the Childhood Live Attenuated Influenza Vaccine (LAIV) and Influenza-related Healthcare Resource Use in England During the 2012 to 2022 Flu Seasons; a Retrospective, Observational Study in the CPRD and HES Databases January 18, 2023 July 4, 2023
NCT06103994 Completed N/A Study to Assess the Effect of Multistrain Probiotic on the Immune Response to the Influenza Vaccination October 27, 2023 January 12, 2024
NCT06118151 Completed Phase 1 Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older April 11, 2022 February 17, 2023
NCT06124131 Completed N/A Building Engagement Using Financial Incentives Trial - Colorectal Cancer Screening November 11, 2023 March 25, 2024
NCT06125717 Completed Phase 1 Phase 1 Evaluation of H1 Influenza Vaccine Delivered by MIMIX MAP July 2, 2022 March 13, 2023
NCT06141824 Completed N/A Performance Evaluation of the Lucira COVID-19 & Flu Test October 11, 2022 February 16, 2023
NCT06252051 Completed Phase 4 Effectiveness of Trivalent Influenza Vaccine (TIV) in Type 2 Diabetes Mellitus (T2DM) Patients With and Without Complications of Chronic Kidney Disease (CKD) January 5, 2021 August 31, 2022
NCT06385821 Completed Phase 3 A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus September 21, 2022 October 9, 2023
NCT00976469 Completed Phase 1/Phase 2 A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents September 2009 March 2011
NCT00976820 Completed Phase 2 Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age October 20, 2009 March 21, 2011
NCT00979251 Completed Phase 2 Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects September 2009 August 2011
NCT00979407 Completed Phase 3 Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1) October 12, 2009 November 4, 2010
NCT00979602 Completed Phase 3 Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older November 9, 2009 February 1, 2011
NCT00980005 Completed Phase 3 Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children October 13, 2009 June 17, 2010
NCT00980109 Completed Phase 4 Long Term Influenza Prophylaxis With Inhaled Zanamivir or Oral Oseltamivir September 2009 September 2010
NCT00980447 Completed Phase 2 Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults October 2009 December 2009
NCT00980850 Completed Phase 2 Swine Flu (Novel Influenza A H1N1) Vaccine Study September 2009 December 2009
NCT00985088 Completed Phase 2 Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older October 11, 2009 December 16, 2010
NCT00985673 Completed Phase 2 Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults October 1, 2009 December 29, 2010
NCT00985790 Completed Phase 2 Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine in Healthy Children October 8, 2009 May 21, 2010
NCT00988143 Completed Phase 2 A Study of Influenza Virus Vaccines in Children and Adults October 2009 March 2010
NCT00988325 Completed Phase 1 A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu Infection January 2011 April 2012
NCT00989287 Completed Phase 3 Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults October 7, 2009 October 26, 2010
NCT00989612 Completed Phase 2 Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) October 1, 2009 April 19, 2010
NCT00992433 Completed Phase 2 H1N1 Vaccine at Two Dose Levels in HIV Positive Adults November 2009 November 2010
NCT00992511 Completed Phase 3 Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes October 14, 2009 November 9, 2010
NCT00992719 Completed Phase 2 Novartis H1N1 Vaccine in Pregnant Women November 2009 February 2011
NCT00992784 Completed Phase 3 Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People October 15, 2009 May 27, 2010
NCT00993083 Completed Phase 2 A Study to Assess the Safety and Efficacy of a New Influenza Candidate Vaccine MVA-NP+M1 In Healthy Adults June 2009 March 2010
NCT00995826 Completed Phase 1 Safety, Tolerability and Pharmacokinetic Study of Multiple Doses of CS-8958 April 2009 November 2009
NCT00996138 Completed Phase 2/Phase 3 Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult Subjects September 2009 November 2009
NCT00996307 Completed Phase 2/Phase 3 Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months October 2009 December 2010
NCT00996853 Completed Post-Authorization Safety Study of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) in the United Kingdom October 31, 2009 April 6, 2011
NCT00996970 Completed Immunogenicity of Novel H1N1 Vaccination Among HIV-Infected Compared to HIV-Uninfected Persons October 2009 December 2022
NCT00999206 Completed Phase 3 Study Measuring the Safety, Immunogenicity and Lot Consistency of Cell Derived Influenza Vaccine January 2010 August 2010
NCT01000584 Completed Phase 4 Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults Receiving Seasonal Influenza Vaccine November 2009 February 2010
NCT01000831 Completed Phase 4 Rapid Evaluation of Pandemic H1N1 Influenza Vaccines in Young Children November 2009 February 2010
NCT01001169 Completed Phase 2 Safety and Immunogenocity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Japanese Children October 1, 2009 May 17, 2010
NCT01001325 Completed Phase 3 Does Seasonal Influenza Vaccination Affect the Incidence of pH1N1 Influenza? October 2009 July 2010
NCT01003145 Completed N/A Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Adults and Elders September 2009 April 2010
NCT01004653 Completed Phase 4 A Clinical Trial of Split-virion Influenza A/H1N1 Vaccines September 2009 November 2009
NCT01006798 Completed Phase 1 Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1 October 2009 September 2011
NCT01007201 Completed N/A Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Pediatric Population October 2009 April 2010
NCT01008137 Completed Phase 4 Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults October 2009 January 2010
NCT01010737 Completed Phase 1/Phase 2 A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers September 2009 March 2010
NCT01010893 Completed N/A Tolerability and Immunogenicity of Fluval P Monovalent Influenza Vaccine August 2009 February 2010
NCT01011049 Completed Phase 2 Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM September 2009 October 2010
NCT01014806 Completed Phase 2 Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults November 2009 May 2010
NCT01023711 Completed N/A Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus November 2009 July 2011
NCT01023776 Completed Phase 4 Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine November 2009 July 2010
NCT01024400 Completed Phase 2 Immunogenicity and Safety of an Inactivated Non-adjuvanted A(H1N1)v Influenza Vaccine in Pregnant Women November 2009 July 2010
NCT01024673 Completed Clinical Characteristics and Outcomes in Patients Diagnosed With Novel Influenza A (H1N1) October 15, 2009 August 19, 2021
NCT01032980 Completed Post Authorization Safety Study of the Pandemic A/H1N1 Influenza Vaccines in Children and Adults December 2009 July 2011
NCT01033734 Completed Phase 1 A Study of Intravenous Tamiflu (Oseltamivir) in Children With Influenza December 2010 December 2012
NCT01033799 Completed N/A Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers October 2006 August 2007
NCT01035749 Completed Phase 2 Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years February 1, 2010 May 10, 2011
NCT01037205 Completed Phase 2 Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza December 2009 September 2011
NCT01037829 Completed Novartis Pandemic Influenza A (H1N1) Vaccine(s) Observational Comparative Safety Study January 2010 November 2010
NCT01039220 Completed N/A Incidence of H1N1v Influenza-like Illness and Risk Factors for Serious Influenza Forms in HIV Infected Patients December 2009 November 2010
NCT01044095 Completed N/A Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza Virus November 2009 June 2012
NCT01046331 Completed Novel Influenza A (H1N1) Surveillance Registry October 2009 October 2010
NCT01047202 Completed Phase 4 Sinovac, Pandemic Influenza A/H1N1 Vaccine in 6 to 35 Months Infants December 2009 May 2010
NCT01050257 Completed Phase 3 A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza January 2010 September 2012
NCT01050465 Completed N/A MedlinePlus Health Prescriptions: Developing a Pragmatic Approach for Clinic Use May 2009 December 2010
NCT01051661 Completed Phase 3 Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age February 12, 2010 September 9, 2011
NCT01052961 Completed Phase 4 A Study on Higher-dose Oseltamivir Treatment's Impact on Viral Clearance and Clinical Recovery in Adults Hospitalized With Influenza January 2010 June 2012
NCT01053143 Completed Phase 3 Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India January 2010 September 2010
NCT01059617 Completed Phase 1 Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults February 9, 2010 October 21, 2011
NCT01063088 Completed Phase 3 Adult Safety Study of 2009/2010 Seasonal Influenza Vaccine February 2010 July 2010
NCT01068912 Completed Phase 2 Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza February 2010 May 2012
NCT01069874 Completed Phase 2/Phase 3 Trial of Vitamin D Supplementation for the Prevention of Influenza and Other Respiratory Infections (ViDiFlu) March 2010 April 2013
NCT01079273 Completed Phase 4 Clinical Study to Evaluate Antibody and Cell Mediated Immunity of A/H1N1 Influenza Vaccine in Healthy Subjects December 2009 November 2010
NCT01083511 Completed Collection and Extraction of Respiratory Specimens March 2010 June 2010
NCT01086566 Completed Phase 1 Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines October 2010 February 2012
NCT01089400 Completed Immuno-virological Characterization of Severe H1N1v Influenza Infection in Bronchoalveolar Lavage October 2009 April 2011
NCT01089660 Completed Phase 2 A Study of the Immunogenicity of Swine-origin A/H1N1 Influenza Vaccine in Healthy Adults March 2010 December 2010
NCT01089816 Completed Rapid Diagnostic Test for Influenza March 2010 October 2010
NCT01096056 Completed Phase 1 Trial to Evaluate the Safety and the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Healthy Children April 5, 2010 December 13, 2010
NCT01100294 Completed N/A Tolerability and Safety Study of FLUVAL P Monovalent Influenza Vaccine in Children September 2009 May 2010
NCT01106196 Completed The Role of Influenza as a Trigger for Acute Myocardial Infarction: a CALIBER Study April 2010 October 2012
NCT01111968 Completed Phase 1 Evaluation of Pandemic Influenza A (H1N1)Candidate Vaccines January 2010 March 2011
NCT01113580 Completed Phase 4 A Clinical Trial of CSL's 2010/2011 Formulation of Enzira® in a Healthy Adult Population May 2010 May 2010
NCT01114620 Completed Phase 4 Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older May 17, 2010 December 9, 2010
NCT01121822 Completed Phase 3 Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intramuscular Route) May 2010 June 2010
NCT01130636 Completed Phase 4 Observational Study on the Pharmacokinetics of Oseltamivir in the Treatment of Influenza During Lactation June 2010 July 2012
NCT01138397 Completed Phase 3 Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route) June 2010 July 2010
NCT01140009 Completed Phase 2 Safety and Protectiveness of the Seasonal Influenza Vaccine for 2010-2011 August 2010 September 2010
NCT01144299 Completed Phase 3 A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults June 17, 2010 July 10, 2010
NCT01146015 Completed Phase 3 Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2010/2011 Season June 2010 July 2010
NCT01146119 Completed Phase 2 Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001) July 2010 June 2011
NCT01146899 Completed N/A FluAlert: Influenza Vaccine Alerts for Providers in the Electronic Health Record December 2009 June 2013
NCT01146912 Completed N/A TextFluenza: Using Technology To Promote Flu Vaccination In Underserved Maternal And Child Populations June 2010 April 2012
NCT01147068 Completed Phase 1/Phase 2 Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults June 2010 October 2011
NCT01153685 Completed Phase 3 Immunogenicity & Safety Study of Fluviral® (2010 - 2011 Season) in Adults Aged 18 to 60 Years and Over 60 Years July 9, 2010 July 31, 2010
NCT01157702 Completed Phase 3 Yearly Strain Variation Study, 2010/2011 July 2010 August 2010
NCT01158326 Completed Phase 3 Evaluation of Efficacy and Safety of Oral Solution Resfenol in Reducing Symptoms of Common Cold And Flu August 2010 November 2011
NCT01161160 Completed Phase 2 Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old July 1, 2010 January 31, 2011
NCT01162122 Completed Phase 3 Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects August 2010 November 2011
NCT01164553 Completed Phase 1 Comparison of Flu Vaccine Doses in Children October 2010 October 2012
NCT01172054 Completed Phase 1 Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults July 2010 November 2011
NCT01173211 Completed Phase 2 2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women September 2010 November 2011
NCT01173224 Completed Phase 1 Influenza Antiviral DAS181-F03 November 2010 September 2011
NCT01181323 Completed Phase 2 Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women September 2011 May 2013
NCT01181336 Completed Phase 1 Phase 1b Influenza Vaccine Study in Healthy Subjects April 2010 July 2010
NCT01182870 Completed Phase 3 Vitamin D and the Influenza Epidemic April 2010 October 2010
NCT01190215 Completed Phase 4 Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previously Been Vaccinated With PandemrixTM October 4, 2010 July 7, 2011
NCT01191853 Completed Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees atBaseline, and After Immunization With the H1N1 or Seasonal Influenza Vaccines September 18, 2009
NCT01192737 Completed "COhort Study on A/H1N1 FLU During PREGnancy" October 2009 November 2010
NCT01195038 Completed Phase 2 Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults October 2010 January 2011
NCT01196026 Completed Phase 4 Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previously Been Vaccinated With Pandemrix™ September 15, 2010 May 26, 2011
NCT01196975 Completed Phase 3 A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults October 1, 2010 June 24, 2011
NCT01196988 Completed Phase 3 Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children October 4, 2010 June 15, 2011
NCT01198756 Completed Phase 3 A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children October 1, 2010 July 1, 2011
NCT01202552 Completed N/A Two-site Intradermal Influenza Vaccination in Elderly October 2010 April 2018
NCT01204671 Completed Phase 3 Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A) October 4, 2010 June 6, 2011
NCT01207557 Completed N/A A Randomized Controlled Trial of the Effectiveness of the Ottawa Influenza Decision Aid August 2009 December 2010
NCT01210898 Completed Phase 3 Immunogenicity and Safety of V70P5 Revaccination Subjects September 2010 December 2011
NCT01215669 Completed Phase 4 Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea October 2010 April 2011
NCT01218308 Completed Phase 3 A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children December 9, 2010 January 9, 2012
NCT01218646 Completed Phase 3 Study of Quadrivalent Influenza Vaccine Among Adults October 2010 April 2011
NCT01222403 Completed Phase 4 A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older October 2010 October 2014
NCT01224262 Completed Phase 1/Phase 2 A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001 September 2010 December 2011
NCT01224301 Completed N/A School Influenza Vaccine vs Standard of Care With Nested Trial of 2 Parent Notification Intensities September 2009 January 2011
NCT01224613 Completed Phase 4 Study to Compare Self-administered and Nurse-administered Intradermal Influenza Vaccine November 2010 February 2011
NCT01226758 Completed Phase 1 Influenza Vaccine Challenge Study in Healthy Subjects June 2010 December 2010
NCT01227421 Completed Phase 2/Phase 3 Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza December 2010 May 2011
NCT01227967 Completed Phase 2 Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications September 2010 March 30, 2017
NCT01229371 Completed Phase 3 Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers October 2010 December 2010
NCT01229397 Completed Phase 3 Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal V October 2010 November 2010
NCT01232868 Completed N/A Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly October 2010 October 2011
NCT01236040 Completed Phase 1 Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old November 29, 2010 August 20, 2012
NCT01239537 Completed Swine Flu (Influenza A H1N1) Follow on Vaccine Study November 2010 December 2010
NCT01240746 Completed Phase 3 Study of Quadrivalent Influenza Vaccine Among Children November 2010 February 2012
NCT01246999 Completed Phase 4 Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children October 2010 June 2013
NCT01248715 Completed Phase 4 Rapid Empiric Treatment With Oseltamivir Study (RETOS) November 2010 May 2016
NCT01249625 Completed N/A The Respiratory Protection Effectiveness Clinical Trial December 2010 March 2018
NCT01249833 Completed Phase 4 Effect of Oseltamivir on Cognitive Function in Subjects With Influenza November 2010 April 2012
NCT01251679 Completed N/A Household Influenza Transmission Study April 9, 2008 November 2013
NCT01258595 Completed Phase 2 A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age November 2010 April 2011
NCT01262079 Completed Evaluation of Influenza-Specific Immune Responses in Children and Adults During the 2010-2011 Influenza Season in the U.S. December 2010 August 2011
NCT01265914 Completed Phase 1 A Study to Evaluate the Safety, Tolerability and Immunogenicity of a Universal Influenza A Vaccine August 2010 August 2011
NCT01271842 Completed Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study October 2010
NCT01282177 Completed Influenza Vaccine Safety and Effectiveness in Healthcare Providers October 2009 June 2012
NCT01298102 Completed Phase 4 Influenza A/H1N1/2009-adjuvanted Vaccine in Renal Disease Patients October 2009 March 2010
NCT01303510 Completed Phase 4 A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2008/2009 Influenza Virus Strains for the Northern Hemisphere July 2008 July 2008
NCT01304563 Completed N/A 2010/2011 Trivalent Influenza Vaccination November 2010 February 2011
NCT01304771 Completed Phase 1 Safety of Synbiotics as Adjuvant to Influenza Vaccine in Elderly December 2010 April 2011
NCT01306253 Completed Phase 4 A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2009/2010 Influenza Virus Strains for the Northern Hemisphere June 2009 June 2009
NCT01306305 Completed Phase 4 A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2010/2011 Influenza Virus Strains for the Northern Hemisphere June 2010 July 2010
NCT01306669 Completed Phase 3 Influenza Vaccine Trial in HIV Uninfected Pregnant Women March 3, 2011 May 2013
NCT01306682 Completed Phase 2/Phase 3 Influenza Vaccination of HIV Infected Pregnant Women: Safety and Immunogenicity March 2011 July 2012
NCT01309568 Completed "Quidel Reader Influenza A + B Test 510(k) and CLIA Waiver Field Study" February 2011 April 2011
NCT01310400 Completed Phase 3 Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young Children October 2009 January 2010
NCT01310413 Completed Phase 3 Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age March 7, 2011 January 26, 2014
NCT01313962 Completed Phase 1 Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects August 2011 January 2012
NCT01317745 Completed Phase 1 H5N1 Mix and Match With MF59 May 2011 September 2012
NCT01317758 Completed Phase 1 H5N1 Mix and Match With AS03 May 2011 September 2012
NCT01318876 Completed Surveillance for Adverse Events Following Influenza Immunization October 2010 February 2011
NCT01320696 Completed Phase 1/Phase 2 Reverse Genetic H9N2 Influenza Vaccine Study in Adults March 2011 May 2012
NCT01323946 Completed Phase 2 Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children April 18, 2011 November 2, 2012
NCT01332578 Completed Phase 4 A Comparison of Solid and Soluble Forms of Cold and Influenza Remedies May 2011 June 2011
NCT01336166 Completed Phase 2 The Long-term Immunogenicity of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine July 2009 July 2011
NCT01342796 Completed Phase 2 Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects May 2011 February 2012
NCT01355172 Completed Phase 4 Immunogenicity and Safety of AdimFlu-S, Formulation 2010-2011, in Infants Aged Between 6-12months Old November 2010
NCT01356316 Completed Phase 4 Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Non-Elderly Adult and Elderly Subjects August 2010 March 2011
NCT01356342 Completed Phase 4 Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Healthy Subjects Aged Over 6 Months Old to 18 Years Old July 2010 May 2011
NCT01357265 Completed Phase 2 Safety and Immunogenicity of One Dose of an Inactivated Trivalent Sub-unit Influenza Vaccine Administered to Non-elderly Adult and Elderly Subjects May 2011 June 2011
NCT01379937 Completed Phase 3 A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children July 28, 2011 October 5, 2012
NCT01389466 Completed Phase 1/Phase 2 Study to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult Volunteers February 2010 December 2011
NCT01389479 Completed Phase 3 Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Healthy Adults January 2005 May 2005
NCT01403649 Completed N/A Collaborative Efforts to Increase Flu Vaccination August 2009 March 2015
NCT01404182 Completed Phase 4 Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine in Adults and Elderly Persons July 2011 August 2011
NCT01406418 Completed Phase 1 Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus February 2013 November 2013
NCT01408290 Completed N/A Safety and Immunogenicity Study of Fluval AB-Like Flu Vaccines With 3.5, 6, 9 or 15 μg HA in Adult and Elderly People September 2011 October 2011
NCT01411358 Completed N/A Immunogenicity and Safety of AdimFlu-S 2011-2012 in Non-Elderly Adult and Elderly Subjects August 2011 March 2012
NCT01412281 Completed Phase 3 Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers October 2011 December 2011
NCT01416571 Completed Phase 2 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults August 12, 2011 September 28, 2012
NCT01416597 Completed A Systematic Review of Studies of the Effect of Influenza Vaccine Against Mismatched Strains August 2011 December 2011
NCT01419925 Completed Phase 2 A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers August 2011 January 2012
NCT01422512 Completed Phase 3 Safety and Immunogenicity of One Dose of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture Administered to Adult and Elderly Subjects September 2011 October 2011
NCT01427309 Completed Phase 4 A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults September 2011 November 2013
NCT01430689 Completed Phase 4 Maternal Flu Vaccine Trial in Bamako, Mali September 12, 2011 January 2014
NCT01430819 Completed Phase 4 Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults September 2011 February 2012
NCT01431768 Completed N/A Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B July 2011 January 2012
NCT01436370 Completed Phase 2 TIV and High Dose TIV in Subjects With Rheumatoid Arthritis October 2011 June 2013
NCT01439360 Completed Phase 3 An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children October 1, 2011 December 31, 2014
NCT01440387 Completed Phase 3 A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older September 30, 2011 October 22, 2011
NCT01455753 Completed The Effect of Proximity on Flu-Shot Participation October 2011 May 2012
NCT01457027 Completed Phase 4 A Study to Assess Immunogenicity Parameters After Vaccination Against Influenza and to Evaluate How These Parameters Change During the Influenza Season October 2011 August 2012
NCT01459276 Completed N/A A Study to Evaluate Safety and Immunogenicity of FluvalAB-like Influenza Vaccine in Non-Elderly Adult and Elderly Subjects October 2011 March 2012
NCT01465035 Completed Phase 1 A Study to Determine the Safety and Immunogenicity of Co-administration of the Candidate Influenza Vaccine MVA-NP+M1 and Seasonal Influenza Vaccine October 2011 November 2012
NCT01472536 Completed N/A A Study of Exclusion Criteria in a University Population November 2011 August 2013
NCT01481454 Completed Phase 3 Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and Adults March 2012 December 2012
NCT01484522 Completed Laboratory Study of Licensed H1N1 Influenza Vaccines in HIV-1 Perinatally Infected Children and Youth October 2009 September 2010
NCT01494740 Completed Phase 2 Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants December 2009 January 2010
NCT01496079 Completed Maternal Immunization: Giving Immunity For Tomorrow December 2011 December 2015
NCT01498718 Completed Phase 1 Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone December 2011 April 2013
NCT01507779 Completed Phase 1 Safety Trial of Monovalent Whole Virus Influenza (H1N1) Vaccine April 2012 December 2012
NCT01511419 Completed Phase 1 Safety Trial of Live Attenuated Influenza (H7N3) Vaccine April 2012 July 2012
NCT01514708 Completed Phase 4 The Safety and Immune Response to Influenza Vaccination in Pregnant Women November 2011 August 2012
NCT01517191 Completed Sentinel Surveillance for Influenza Requiring Hospital Admission Canadian Adults November 2011 December 2016
NCT01520935 Completed Influenza Burden Assessment in the United Kingdom, 1996-2008 September 2011 May 2012
NCT01521416 Completed Cost of Illness Associated With Influenza in the UK June 2011 April 2013
NCT01527825 Completed Phase 3 Immunogenicity and Safety of Different Dosing Schedules of Trivalent Influenza Vaccine in HIV-infected Pregnant Women September 2012 June 2014
NCT01538940 Completed Phase 4 Immunogenicity of Influenza Vaccines in HIV-infected Persons in Thailand November 1, 2011 October 2015
NCT01545349 Completed Phase 1 Safety of Lactobacillus Rhamnosus GG Versus Placebo in Elderly Subjects Receiving Live Attenuated Influenza Vaccine February 2012 May 2013
NCT01551810 Completed Phase 3 The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated) March 2012 August 2012
NCT01551823 Completed Phase 3 The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated) （Children Forms of Drug） March 2012 August 2012
NCT01554813 Completed Phase 3 Clinical Trial of Inactivated Influenza Vaccine (0.5ml Formulation) May 2006 October 2006
NCT01554826 Completed Phase 3 Clinical Trial of the Inactivated Influenza Vaccine (0.25ml Formulation for Pediatric Use) March 2009 February 2010
NCT01560793 Completed Phase 1 Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years June 2012 November 2013
NCT01561768 Completed Phase 2 A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults March 2012 January 2013
NCT01573312 Completed Phase 1 H5N1 Vaccination With and Without AS03: Systems Biology Analysis May 24, 2012 January 2, 2014
NCT01578317 Completed Phase 1/Phase 2 Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant March 20, 2012 January 31, 2016
NCT01579916 Completed Phase 4 A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults May 2012 November 2012
NCT01580033 Completed Phase 3 Phase 3 Study of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine April 2012 November 2012
NCT01584908 Completed Adjuvanted Influenza Vaccine Evaluation in Kidney Transplant Recipients August 2012 November 2014
NCT01592799 Completed N/A Study on the Burden of Influenza-related Hospitalizations and Emergency Room (ER) Visits in Children in Spain November 23, 2010 May 23, 2011
NCT01599390 Completed Influenza Burden Assessment in the United States, July1997 - up to April 2009 July 2012 February 2013
NCT01607112 Completed Phase 3 A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2012/2013 in People Aged 18 Years and Above July 10, 2012 July 31, 2012
NCT01609998 Completed Phase 1 Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents June 2012 July 2013
NCT01610245 Completed Phase 3 Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza March 2013 April 16, 2015
NCT01612000 Completed Phase 1/Phase 2 Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults May 2012 December 2013
NCT01617239 Completed Phase 1 Clinical Study for Safety and Immunogenicity Study of Influenza Vaccine June 2012 December 2013
NCT01623518 Completed Phase 1 A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine ChAdOx1-NP+M1 June 2012 March 2013
NCT01625689 Completed Phase 2 Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine June 2012 February 2013
NCT01626820 Completed Phase 3 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral® (2012/2013 Season) in Adults July 19, 2012 August 10, 2012
NCT01631071 Completed N/A Re-licensing Study to Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza Strains July 2012 August 2012
NCT01631110 Completed Phase 3 Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains July 2012 August 2012
NCT01640314 Completed Phase 3 Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above July 2012 August 2012
NCT01640327 Completed Phase 3 Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults Aged 18 Years and Above July 2012 August 2012
NCT01646138 Completed Phase 1/Phase 2 Influenza A 2009 H1N1 Challenge Study in Healthy Adults February 2012 December 2013
NCT01649713 Completed Phase 4 Yearly Licence Tolerability and Immunogenicity Study of Fluval AB Seasonal Influenza Vaccine to be Used in the 2012/2013 Vaccination Season August 2012 September 2012
NCT01651494 Completed Phase 1 Influenza Antiviral DAS-181-F04 in Healthy Adults August 12, 2011 September 18, 2012
NCT01653015 Completed Phase 4 Live Versus Inactivated Influenza Vaccine Study in Hutterite Children November 2012 December 2015
NCT01654224 Completed Phase 4 Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting November 2011 June 2014
NCT01654809 Completed Phase 4 Safety and Immunogenicity Study of Split Influenza Virus Vaccine in Different Age Groups August 2010 June 2011
NCT01658800 Completed Phase 1 Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 September 2012 December 2013
NCT01659086 Completed Phase 1 Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age August 22, 2012 March 19, 2014
NCT01662583 Completed N/A Vaccine Health Literacy Related Text Message Reminders to Increase Receipt of Second Dose of Influenza Vaccine for Young, Low Income, Urban Children September 2012 June 2013
NCT01664793 Completed N/A From Innovation to Solutions: Childhood Influenza Vaccination Planning October 2010 November 2013
NCT01665807 Completed Phase 4 A Time-motion Study Comparing Self- to Nurse-vaccination With Influenza Vaccine September 2012 December 2012
NCT01676402 Completed Phase 1 Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years August 2012 April 2014
NCT01680679 Completed Phase 4 Influenza Immunization of Children in India May 2012 May 2014
NCT01682369 Completed Phase 2 ADITEC FLU STUDY: Understanding the Genetic Basis for Immune Responses September 2012 January 2015
NCT01683630 Completed Comparison of Epidemiology and Clinical Outcomes of Influenza A & B Cases in Manitoba, Canada April 2012 September 2012
NCT01688297 Completed Phase 1 Safety Study of an Oral Vaccine to Prevent Seasonal Influenza September 2012 April 2015
NCT01691326 Completed Phase 4 Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) September 2012 February 2013
NCT01691339 Completed Phase 4 Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults. September 2012 February 2013
NCT01693380 Completed Phase 4 Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza May 2009 November 2009
NCT01702454 Completed Phase 3 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine When Administered in Children Who Previously Participated in Study 115345 October 6, 2012 June 5, 2013
NCT01707602 Completed Phase 1/Phase 2 Routes of Immunization and Flu Immune Responses October 2012 April 2013
NCT01711736 Completed Phase 3 Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of Age November 1, 2012 June 19, 2013
NCT01712984 Completed Phase 3 Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years October 2012 October 2013
NCT01715792 Completed Assess the Risk of Solid Organ Transplant Rejection Following Vaccination With Pandemrix™ in UK October 2012 August 2013
NCT01715909 Completed Phase 1 A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection January 22, 2014 June 17, 2018
NCT01719783 Completed Phase 1 Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza Vaccine September 2012 January 2013
NCT01720277 Completed Phase 4 High Dose Influenza Vaccine in Nursing Home - Pilot Study September 2012 May 2016
NCT01720329 Completed N/A Use of Probiotics to Prevent Influenza July 2013 October 2017
NCT01728090 Completed Phase 4 Effectiveness of a Handwashing Programme in the Prevention of School Absenteeism Due to Respiratory Infections October 2009 May 2010
NCT01728753 Completed Phase 1/Phase 2 T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza November 2012 February 2013
NCT01730378 Completed Phase 4 Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old December 5, 2012 December 17, 2013
NCT01736709 Completed Phase 4 The Immunogenicity and Safety of 2012-2013 Trivalent Seasonal Influenza Vaccine November 2012 May 2013
NCT01740063 Completed Phase 2 Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza November 2012 January 2014
NCT01746082 Completed Phase 2 Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Adult and Elderly Populations January 2013 August 2013
NCT01747148 Completed Phase 1 Testing the AVI-7100 Flu Drug in Healthy Volunteers December 8, 2012 June 29, 2016
NCT01752881 Completed Phase 4 Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly Subjects August 2012 September 2012
NCT01755364 Completed Phase 3 A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Healthy Subjects Aged Over 3 Years Old to 18 Years Old November 1, 2012 March 2013
NCT01756950 Completed Phase 1 Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses January 2013 November 2013
NCT01759654 Completed Phase 3 A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Non-Elderly Adults and Elderly Subjects October 24, 2012 March 2013
NCT01761734 Completed N/A Pilot Text Message for Influenza Vaccination January 2013 May 2013
NCT01761799 Completed N/A Protecting Pregnant Women From Infectious Diseases December 2012 August 2015
NCT01767337 Completed N/A Intracutaneous Delivery of Varied Dose Volumes of Saline December 2012 December 2012
NCT01767896 Completed Phase 3 Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine October 2012 March 2013
NCT01772901 Completed N/A Brief Influenza Vaccine Education to Pregnant Women October 2013 July 2015
NCT01773928 Completed Phase 3 Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived) January 2013 April 2013
NCT01774032 Completed Phase 3 H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and Older March 2013 October 2013
NCT01779570 Completed Phase 4 Anti-inflammatory Effects of Macrolide Treatment in Influenza Lower Respiratory Tract Infections February 2013 April 2016
NCT01788228 Completed Phase 3 Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure March 22, 2013 February 25, 2015
NCT01788514 Completed N/A Combining Entertainment & Influenza Education for Pediatric Patients January 2013 May 2014
NCT01793883 Completed Phase 2 Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza May 2013 May 2014
NCT01797029 Completed Phase 3 A Randomized, Controlled Trial on the Efficacy and Safety of Live-Attenuated Influenza Vaccine (LAIV) Among Children in Bangladesh February 2013 September 2014
NCT01804946 Completed Phase 4 Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza February 2011 October 2014
NCT01811823 Completed Phase 4 Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults March 31, 2014 November 20, 2014
NCT01812980 Completed Phase 4 Immunogenicity and Safety of Trivalent Influenza Vaccine in Non-pregnant HIV-infected Women May 2013 July 2013
NCT01816464 Completed Phase 4 Immunogenicity and Safety of Trivalent Influenza Vaccine in Pregnant and Nonpregnant HIV Uninfected Women September 2013 April 2014
NCT01819155 Completed Phase 2 Immunogenicity and Safety Trial of Adjuvanted and Non-adjuvanted Trivalent Influenza Vaccine in Tropical Africa April 2013 September 2013
NCT01825200 Completed Phase 3 Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age March 2013 May 2013
NCT01827462 Completed Phase 4 Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017) October 2007 March 2017
NCT01839760 Completed Evaluation of Viral Shedding Patterns and Clinical Outcomes of Influenza Patients December 2012 January 2014
NCT01842997 Completed Phase 4 Safety of H1N1 Influenza Vaccination in Pregnant Women October 2009 December 2010
NCT01850446 Completed Phase 4 Comparative Clinical Trial of Efficacy and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza February 20, 2015 April 16, 2018
NCT01854632 Completed Phase 3 Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal May 2013 December 2013
NCT01857206 Completed Phase 3 Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age May 2013 June 2014
NCT01859143 Completed Phase 4 Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults May 2013 December 2013
NCT01867021 Completed Phase 4 Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and Above May 2013 December 2013
NCT01878812 Completed Phase 3 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine, Fluarix/Influsplit Tetra® (2013/2014 Season), in Adults 18 Years of Age and Older July 11, 2013 August 5, 2013
NCT01878825 Completed Phase 3 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and Older July 18, 2013 August 9, 2013
NCT01884519 Completed Phase 3 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix®/Influsplit SSW® (2013/2014 Season), in Adults 18 Years of Age and Older July 1, 2013 August 2, 2013
NCT01891084 Completed Phase 4 The Benefit and Harm of Fever Suppression by Antipyretics in Influenza July 2013 December 2018
NCT01892631 Completed N/A Text Messaging Reminders for Influenza Vaccine in Primary Care September 2013 December 2015
NCT01893177 Completed Phase 3 Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (2013-14) July 2013 August 2013
NCT01906593 Completed A Post-marketing Safety Study of Beijing Tiantan Biological's Influenza Virus Vaccine in Elderly June 2013 July 2013
NCT01911754 Completed Phase 3 Japanese Pediatric H5N1 Vaccine Study August 2013 April 2014
NCT01916759 Completed N/A Differences in Response to the Flu Vaccine Among Adults With HIV and Without HIV in Uganda June 2013 March 2014
NCT01933048 Completed Phase 4 Self-Administered Nasal Influenza Feasibility Study September 2012 October 2013
NCT01934127 Completed Phase 1 Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age August 26, 2013 October 20, 2014
NCT01938170 Completed N/A Home Administration of FluMist by Parents/Caregivers September 2014 September 2015
NCT01938352 Completed Phase 2 Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza Challenge October 2, 2013 January 22, 2014
NCT01938742 Completed Phase 2 H7N9 Mix and Match With MF59 in Healthy Adults September 2013 November 2014
NCT01942265 Completed Phase 2 H7N9 Mix and Match With AS03 and MF59 in Healthy Adults September 2013 January 2015
NCT01945424 Completed Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry August 16, 2013 September 15, 2019
NCT01946425 Completed Phase 4 Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine September 2013 July 2014
NCT01946438 Completed Phase 4 Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults September 2013 July 2014
NCT01947049 Completed N/A Influenza Diagnosis, Treatment and Surveillance With Xpert Flu July 2013 June 30, 2014
NCT01949090 Completed Phase 2 Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older September 25, 2013 October 23, 2014
NCT01959945 Completed Phase 3 Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation) November 2013 October 2014
NCT01961947 Completed Phase 3 Study of ASP7374, Cell-culture-derived Influenza Vaccine October 2013 November 2013
NCT01961960 Completed Phase 3 A Study to Evaluate Intramuscular ASP7374 October 2013 November 2013
NCT01967784 Completed Phase 3 Study of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in Taiwan October 2013 July 2014
NCT01971255 Completed Phase 1/Phase 2 Evaluation of Anti-Hemagglutinin (Anti-HA) Antibodies as Protection From the Flu in Healthy People September 2013 September 2015
NCT01974895 Completed Phase 2 Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age October 23, 2013 July 3, 2014
NCT01982331 Completed Phase 1 Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/CALIFORNIA/66/395 (H2N2) Influenza Vaccine October 2013 March 2014
NCT01984125 Completed N/A Testing the Use of Prompts to Increase Adolescent Immunization Rates April 2011 December 2013
NCT01987011 Completed Phase 3 Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers August 2013 March 2014
NCT01987349 Completed Phase 4 T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009 September 2009 January 2010
NCT01990846 Completed Phase 1 Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects March 2014 February 2015
NCT01992094 Completed Phase 3 Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older November 2013 July 2014
NCT01992107 Completed Phase 3 Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old November 2013 August 2014
NCT01995851 Completed Randomized Controlled Trial of LAIV vs TIV Vaccines in Schools October 2013 April 2014
NCT01998477 Completed Phase 3 A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications October 2013 July 2014
NCT01999842 Completed Phase 1 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age November 25, 2013 January 19, 2015
NCT02008344 Completed Phase 3 Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults December 2013 January 2015
NCT02008578 Completed Phase 1 Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot) December 2013 June 2014
NCT02019732 Completed Study to Assess the Burden of Mild Outcomes (Physician Office Visits) Due to Influenza in the United States January 2013 June 2013
NCT02026349 Completed Phase 3 Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316 January 2014 March 2015
NCT02035696 Completed Phase 1/Phase 2 Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old December 2013 December 2014
NCT02045472 Completed Phase 1 A Study of VIS410 to Assess Safety and Pharmacokinetics September 2014 May 2015
NCT02056340 Completed Phase 2 Statin Therapy in Acute Influenza October 2013 June 30, 2018
NCT02062281 Completed Phase 4 Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults November 2013 January 2014
NCT02069496 Completed Drug Use Investigation for Arepanrix® (H1N1) February 2010 October 2010
NCT02100436 Completed Phase 2 Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations June 11, 2014 March 20, 2015
NCT02107807 Completed Phase 3 Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine April 2014 May 2015
NCT02111252 Completed Phase 1/Phase 2 A Phase 1/2 Study of a Intramuscular Injection of TAK-850 in Healthy Adult Subjects March 2014 April 2014
NCT02121782 Completed Phase 1/Phase 2 A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine) May 2014 June 2014
NCT02124096 Completed Zoonotic Influenza Infections of Swine Origin at Ohio Agricultural Fairs April 25, 2014 June 17, 2019
NCT02126761 Completed Phase 1 Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above June 2014 November 2015
NCT02133456 Completed A Post-marketing Safety Study of Inactivated, Split-virion Influenza Vaccine in Subjects Aged 3 Years and Older January 2014 April 2014
NCT02133781 Completed Phase 4 B-cell Immunity to Influenza (SLVP017)- Year 1, 2009 July 2009 December 2009
NCT02134184 Completed Phase 4 The Influence of Chronic CMV Infection on Influenza Vaccine Responses October 2012 December 2012
NCT02136017 Completed Post-License Safety Evaluation of Influenza Virus Vaccine January 2013 December 2013
NCT02141581 Completed Phase 4 Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014) August 2011 December 2014
NCT02148211 Completed Fluarix/ FluLaval/ Fluarix Quadrivalent/ FluLaval Quadrivalent Vaccine Pregnancy Registry June 1, 2014 May 31, 2019
NCT02148328 Completed Phase 1 Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults May 2014 October 2014
NCT02151201 Completed N/A Impact of Influenza Vaccination in Pregnancy Video Education November 2013 January 2014
NCT02154061 Completed N/A Systems Biology of Flu Vaccine in Healthy Adults With and Without the Use of Antibiotics April 2015 May 26, 2017
NCT02206464 Completed Phase 1 H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo... July 29, 2014 January 7, 2016
NCT02207413 Completed Phase 3 A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children August 18, 2014 April 18, 2015
NCT02215863 Completed Phase 4 Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years September 2014 March 2015
NCT02218697 Completed Phase 3 Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older October 1, 2014 May 4, 2015
NCT02222870 Completed Phase 4 Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine August 2014 June 2015
NCT02228980 Completed Phase 4 Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China September 2014 October 2015
NCT02242643 Completed Phase 3 Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age October 1, 2014 June 23, 2015
NCT02243774 Completed N/A Mail Outreach To Increase Vaccination Acceptance Through Engagement September 2014 September 2015
NCT02249221 Completed Phase 1/Phase 2 Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine) October 2014 November 2014
NCT02255279 Completed Phase 3 Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico. October 2014 May 2015
NCT02255409 Completed Phase 3 Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05 October 2014 January 2016
NCT02258334 Completed Phase 4 Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults October 2014 December 2014
NCT02263027 Completed Phase 4 Do Some Healthy Adults Consistently Have Systemic Reactions to Influenza Vaccines? October 2014 January 2016
NCT02263040 Completed Phase 1/Phase 2 A Pilot Study to Assess the Immunogenicity and Reactogenicity of High Versus Standard Dose TIV October 2014 December 31, 2016
NCT02266277 Completed N/A System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts November 2014 December 2016
NCT02267733 Completed Phase 1 Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients October 2014 December 2015
NCT02269007 Completed Phase 1 A Phase I Clinical Trial for Inactivated Quadrivalent Influenza Vaccine (Split Virion) in Healthy Adults in China May 2015 September 2015
NCT02269852 Completed Phase 4 The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza Vaccine December 2013 June 2014
NCT02284594 Completed N/A Adult Influenza Vaccination Text Message Reminders With Electronic Health Record Alerts November 2014 March 2015
NCT02285998 Completed Phase 3 Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age October 2014 May 2015
NCT02290509 Completed Phase 3 Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age October 2014 May 2015
NCT02293317 Completed Phase 2 Phase II Study to Assess Safety & Immunogenicity of Multimeric-001 Influenza Vaccine, Followed by TIV November 2014 June 2015
NCT02293863 Completed Phase 2 A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection January 14, 2015 May 23, 2017
NCT02302924 Completed Evaluation of Psychometric Testing Properties of Severity Symptom Grading Scale of Influenza Infection: Flu-PRO Stage III September 2014 May 2015
NCT02307851 Completed Phase 2 Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults November 2014 June 2015
NCT02313740 Completed Prospective Cohort Study to Evaluate Safety/Immunogenicity of Butantan Influenza Vaccine in Healthy Adults/Elderly April 2015 June 2015
NCT02334514 Completed The Effect of Oseltamivir Treatment on the Yield of Polymerase Chain Reaction Test for Confirmed Influenza Infection November 2014 July 30, 2017
NCT02335164 Completed Phase 1 A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults July 2015 May 1, 2019
NCT02350751 Completed Phase 1 Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults January 2015 June 2015
NCT02352584 Completed Phase 3 A Multicenter, Double-blind, Parallel Phase III Study October 2014 July 2015
NCT02362919 Completed Influenza Vaccination Among the Elderly Individuals February 2015 May 2016
NCT02366962 Completed Phase 3 A Study to Assess the Safety of ASP7374 in Adult Subjects Aged 20 or Older February 2015 April 2015
NCT02369159 Completed Phase 3 Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza March 11, 2015 May 14, 2020
NCT02369341 Completed Phase 3 Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above April 29, 2015 June 3, 2015
NCT02381418 Completed Phase 3 Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season March 2015 March 2015
NCT02392858 Completed N/A Severe Influenza Cohort January 16, 2015 January 2019
NCT02423577 Completed Phase 2 Safety and Protective Efficacy of FF-3 Dry Powder in Healthy Subjects Infected With Influenza Challenge Strain September 2015 June 2016
NCT02438423 Completed Phase 1 Inactivated Influenza Vaccine Delivered by Microneedle Patch or by Hypodermic Needle June 2015 March 23, 2016
NCT02451358 Completed Phase 3 Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India July 27, 2015 January 28, 2017
NCT02459171 Completed Household Transmission of Zoonotic Influenza Viruses in a Cohort of Egyptian Poultry Growers August 5, 2015 April 23, 2022
NCT02464163 Completed Phase 1/Phase 2 Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older July 2015 August 2016
NCT02467842 Completed Phase 3 Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects October 2014 May 2015
NCT02468115 Completed Phase 2 Influenza Challenge Study of VIS410 in Healthy Volunteers May 2015 February 2016
NCT02473510 Completed Phase 4 Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season June 2015 January 2016
NCT02480101 Completed Phase 1 Reactogenicity, Safety and Immunogenicity of a LAIV H7N9 Influenza Vaccine October 2014 April 2015
NCT02487147 Completed N/A Evaluation of Free Air Portable Air Powered Respirator November 14, 2016 December 12, 2016
NCT02522754 Completed Phase 1/Phase 2 Development of an Intranasal Proteosome Influenza Vaccine January 2002 January 2004
NCT02525055 Completed N/A Characterisation of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model January 2014 August 11, 2014
NCT02529904 Completed Phase 2 ADITEC FLU 2 STUDY: Understanding the Genetics Basis for Immune Responses to Flu Vaccines in Children and Adults August 2015 April 2016
NCT02539108 Completed Phase 4 Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children August 2015 July 2016
NCT02541253 Completed Phase 3 A Study to Evaluate the Efficacy and Safety of 'GC3110A(QIV)' in Healthy Children September 2015 June 2016
NCT02550197 Completed Phase 3 Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years September 2015 July 2016
NCT02553343 Completed Phase 2 A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older September 2015 April 4, 2016
NCT02554409 Completed Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry October 13, 2015 April 30, 2019
NCT02557802 Completed N/A T-cell Diversity Following Intranasal and Intramuscular Vaccines October 2015 January 2016
NCT02559505 Completed N/A Influenza Immunity in Children October 2015 July 3, 2020
NCT02563093 Completed Phase 4 Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults September 2015 July 2016
NCT02566265 Completed Phase 2 Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients September 2015 June 2018
NCT02567721 Completed Post-authorisation Safety Study (PASS) of Influenza Vaccine in United Kingdom (UK) October 2015 November 2015
NCT02583256 Completed Phase 3 Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989) January 29, 2016 May 9, 2017
NCT02584036 Completed Project IMPACT Immunizations (IMProving America's Communities Together) October 2015 July 2016
NCT02586792 Completed Phase 2 H7N9 Boost in Healthy Adults January 12, 2016 December 29, 2016
NCT02587221 Completed Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age September 30, 2016 July 23, 2018
NCT02588521 Completed Phase 1 A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study August 31, 2015 August 14, 2017
NCT02592486 Completed Phase 4 The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine November 2015 August 2016
NCT02597647 Completed Phase 1 Bacterial Composition and Immune Responses in the Nose and Oropharynx During Influenza Infection February 2011 April 2014
NCT02603952 Completed Phase 1/Phase 2 A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza December 7, 2015 December 9, 2016
NCT02609399 Completed Phase 4 ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir November 1, 2015 May 31, 2018
NCT02612922 Completed Phase 3 Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza December 2015 September 4, 2016
NCT02623075 Completed Phase 1/Phase 2 Influenza Vaccine Responses as a Means of Assessing Immune Competence in Chimeric Kidney/Stem Cell Transplant Recipients October 2015 December 2023
NCT02624219 Completed Phase 1 H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults August 16, 2016 January 30, 2018
NCT02635724 Completed Phase 3 Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza December 2015 September 2018
NCT02640989 Completed Phase 4 Safety and Immunogenicity of Three Seasonal Trivalent Influenza Vaccines in China Military October 2014 April 2015
NCT02644018 Completed Phase 3 Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o. January 2016 May 2016
NCT02665351 Completed Phase 2/Phase 3 Peramivir Treatment Response in Adults Hospitalized for Influenza-associated Lower Respiratory Tract Infections February 2011 March 2014
NCT02677493 Completed Phase 3 Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.' October 2015 June 2016
NCT02686398 Completed Phase 4 Immunogenicity of a Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Undergoing Hemodialysis October 2013 November 2014
NCT02691130 Completed Phase 2 Assess the Safety and Immunogenicity of M-001 as A Standalone Influenza Vaccine and as A H5N1 Vaccine Primer in Adults November 2015 January 2017
NCT02710409 Completed Phase 3 A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older January 2016 August 2016
NCT02719743 Completed Phase 2 A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age July 7, 2016 February 13, 2018
NCT02743117 Completed Phase 4 Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season May 2, 2016 November 30, 2016
NCT02743676 Completed A Retrospective, Observational Registry of Participants With Avian Influenza Infection January 2007 March 2012
NCT02746211 Completed Phase 1/Phase 2 Influenza Challenge Study in Healthy Volunteers January 2008 December 2008
NCT02819115 Completed Cohort Study to Evaluate Safety and Immunogenicity of Butantan Seasonal Influenza Vaccine June 2013 July 2013
NCT02819180 Completed Study to Evaluate Safety and Immunogenicity of Butantan Seasonal Influenza Vaccine - FLU-02-IB April 2014 June 2014
NCT02846311 Completed Evaluation of the Alere i Influenza A&B Nucleic Acid Amplification Versus Xpert Flu/RSV January 2015 April 2015
NCT02868658 Completed N/A Asymptomatic Flu Project October 4, 2016 March 21, 2017
NCT02876159 Completed Phase 4 The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination July 2016 December 1, 2016
NCT02877160 Completed Phase 1 A Study to Assess the PK of AL-794 Formulations in Healthy Subjects June 30, 2016 May 31, 2017
NCT02882100 Completed Phase 4 Adjuvanted Influenza Vaccination in U.S. Nursing Homes April 2016 January 25, 2023
NCT02894840 Completed Phase 1/Phase 2 Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults November 2015 November 2016
NCT02907580 Completed N/A Influenza Vaccine Attitudes, Intent, and Receipt: Pediatric September 13, 2016 June 1, 2017
NCT02907645 Completed N/A Influenza Vaccine Randomized Educational Trial: Adult October 6, 2016 June 1, 2017
NCT02908269 Completed Phase 4 Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations September 15, 2016 December 9, 2016
NCT02909842 Completed N/A Effect of Drinking Fermented Milk on Immune Response January 1, 2016 August 1, 2017
NCT02915302 Completed Phase 4 Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children September 23, 2016 March 6, 2017
NCT02918006 Completed Phase 2 A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine August 31, 2016 January 19, 2018
NCT02921997 Completed Phase 2 H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses November 7, 2016 February 14, 2018
NCT02935192 Completed Phase 3 Phase 3 Trial of Serbian Seasonal Influenza Vaccine November 28, 2016 March 25, 2017
NCT02949011 Completed Phase 3 Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications January 11, 2017 April 20, 2018
NCT02954354 Completed Phase 3 A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza December 8, 2016 April 24, 2017
NCT02955030 Completed Phase 1 Evaluation of the Safety and Immunogenicity of a Sublingual Influenza Vaccine NSV0001 in Healthy Male Volunteers October 2016 September 2017
NCT02962908 Completed Phase 2 A Randomised, Double-blind, Placebo-controlled Phase IIb Trial to Test FLU-v Vaccine August 2016 July 18, 2017
NCT02964065 Completed Phase 3 A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV) November 2016
NCT02972957 Completed Phase 4 A Study of Intranasal Live Attenuated Influenza Vaccine Immunogenicity and Associations With the Nasopharyngeal Microbiome Among Children in the Gambia January 30, 2017 May 23, 2019
NCT02979626 Completed Evaluation of Moderate to Severe Influenza Outcomes in Children January 30, 2017 May 5, 2018
NCT02979730 Completed N/A Impact of Rapid Flu Testing in BMC ED February 7, 2017 December 1, 2017
NCT02983019 Completed Treatment of Influenza in Routine Clinical Practice December 2013 September 2016
NCT02987374 Completed Phase 4 Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV Immunization May 2012 December 2012
NCT02989194 Completed Phase 2 Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A January 6, 2017 October 27, 2017
NCT03010007 Completed Prospective Analysis of Seasonal Influenza - Viral Transmission and Evolution in the City of Basel, Switzerland January 2017 May 2018
NCT03016143 Completed Phase 2 Immunogenicity and Safety Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI) October 2016 December 2016
NCT03020498 Completed Phase 4 B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011) September 2010 December 2011
NCT03020537 Completed Phase 4 B-cell Immunity to Influenza (SLVP017)- Year 5, 2013 October 2013 December 2013
NCT03022396 Completed Phase 4 T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 2, 2010 September 2010 January 2011
NCT03022422 Completed Phase 4 T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 3, 2011 September 2011 December 2011
NCT03022435 Completed Phase 4 T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012 October 2012 January 2013
NCT06229444 Enrolling by invitation N/A Predict + Protect Study: Exploring the Effectiveness of a Predictive Health Education Intervention on the Adoption of Protective Behaviors Related to ILI February 12, 2024 December 2024
NCT04672577 Not yet recruiting Infection Tracking in Travellers. The Project Aims to Identify Profiles of Travel-associated Illness and to Follow up on Long-term Sequelae of Arboviral Infections and Malaria January 30, 2021 December 31, 2025
NCT05832307 Not yet recruiting N/A The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program August 1, 2024 July 31, 2027
NCT06075732 Not yet recruiting N/A ACTIVATE in Public Housing July 1, 2024 December 31, 2029
NCT06274359 Not yet recruiting N/A Digital Storytelling to Reduce Pediatric Influenza Vaccination Disparities May 1, 2024 August 31, 2027
NCT06460064 Not yet recruiting Phase 1 First-in-human Study to Assess the Safety, Tolerability and Immunogenicity of the Adjuvanted Universal Influenza Vaccine fH1/DSP-0546LP June 26, 2024 March 27, 2026
NCT06207058 Not yet recruiting Evaluation of a Screen and Treat Protocol for Influenza January 15, 2024 July 1, 2024
NCT05947071 Not yet recruiting Phase 2 High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients August 1, 2024 September 1, 2027
NCT05569239 Not yet recruiting Phase 2 Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg April 1, 2023 July 1, 2024
NCT06254313 Not yet recruiting The Role of Cxcr4Hi neutrOPhils in InflueNza September 2024 September 2026
NCT05612893 Not yet recruiting Discover the Immune Signature of Sepsis Caused by Acute Pulmonary Infection: A Cohort Study November 16, 2022 September 10, 2025
NCT03323112 Recruiting Immune Responses in Health Care Personnel October 18, 2017 October 14, 2027
NCT04471493 Recruiting Pediatric and Ambulatory Research in Infectious Diseases June 26, 2017 August 2, 2030
NCT06029933 Recruiting Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years August 17, 2023 May 2026
NCT05332899 Recruiting Phase 1 Influenza Human Challenge Model May 24, 2022 March 2025
NCT05040659 Recruiting Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2 November 14, 2022 May 1, 2025
NCT06168019 Recruiting Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in India December 26, 2023 June 2028
NCT05666245 Recruiting N/A DMID 21-0041; Influenza CVD 59000 February 20, 2023 January 2028
NCT05648448 Recruiting Phase 2 A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza February 22, 2023 January 1, 2027
NCT06161454 Recruiting Phase 4 Xofluza-Wearables Feasibility-Study December 14, 2023 May 31, 2024
NCT06183229 Recruiting Phase 3 Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza September 15, 2023 October 1, 2025
NCT03900988 Recruiting Phase 3 Intravenous N-acetylcysteine and Oseltamivir Versus Oseltamivir in Adults Hospitalized With Influenza and Pneumonia May 8, 2023 December 31, 2025
NCT05616546 Recruiting Phase 4 Bone Marrow and Peripheral Blood Immune Responses Study October 16, 2023 December 2029
NCT05866237 Recruiting N/A COVID-19 Vaccine Uptake Amongst Underserved Populations in East London January 1, 2024 October 1, 2024
NCT05170009 Recruiting Phase 2/Phase 3 Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza April 22, 2022 September 2026
NCT05613751 Recruiting N/A Enhancing Protection Against Influenza and COVID-19 for Pregnant Women and Medically at Risk Children October 26, 2022 December 31, 2024
NCT04101838 Recruiting Phase 4 B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults April 1, 2021 May 2025
NCT04868188 Recruiting Pharmacokinetics of Voriconazole in Adult ECMO Patients August 24, 2021 June 30, 2024
NCT05084846 Recruiting InFLUenza and the HEART An Investigation Into the Acute and Lasting Cardiac Effects of Influenza Infection January 1, 2022 March 31, 2025
NCT05215327 Recruiting Phase 2 High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients November 7, 2022 December 2027
NCT05765838 Recruiting N/A Combined Molecular Testing for Influenza, SARS-CoV-2, and RSV RNA From Different Upper Airway Specimens. March 3, 2023 July 1, 2023
NCT01386424 Recruiting Screening for LID Clinical Studies Unit Healthy Volunteer Protocols July 20, 2011
NCT06160128 Recruiting COVID-19 Pharmacotherapy Effectiveness in the VA Healthcare System September 26, 2022 September 30, 2027
NCT04794829 Recruiting Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination August 19, 2021 December 31, 2026
NCT04772170 Recruiting Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies October 23, 2023 June 2, 2025
NCT05582239 Recruiting Measure of Vaccine Effectiveness to Prevent Hospitalizations for Viral Respiratory Infections in Adults January 20, 2023 January 20, 2026
NCT04712539 Recruiting Phase 2 Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients October 11, 2021 February 28, 2028
NCT03901001 Recruiting Phase 3 Adjunctive Sirolimus and Oseltamivir Versus Oseltamivir Alone for Treatment of Influenza May 8, 2023 December 31, 2025
NCT06179446 Recruiting Phase 1 A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza December 13, 2023 November 30, 2024
NCT05765396 Recruiting SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies May 15, 2023 April 30, 2025
NCT05239403 Recruiting Association Between Gut Microbiome and Dietary Determinants and Vaccine Response August 24, 2021 February 28, 2025
NCT05755620 Recruiting Phase 1 A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults April 5, 2023 August 20, 2025
NCT06141655 Recruiting Phase 4 HD vs SD Quadrivalent Influenza Vaccine in Adults Aged 65 to 79 Years in Galicia October 26, 2023 August 2025
NCT05266222 Recruiting Respiratory Virus Sampling and Repository August 11, 2022 December 31, 2031
NCT05565586 Recruiting N/A Impact of High Dietary Fiber on Microbiome and Vaccine Responses August 23, 2022 January 2, 2029
NCT06342349 Recruiting Phase 1 A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above. March 30, 2024 December 30, 2024
NCT05944705 Recruiting Commercially Available Cannabis Products for Immune Support November 1, 2023 December 1, 2024
NCT06259487 Recruiting N/A Coordinated Vaccination Against RSV and Influenza in Patients With Chronic Heart Failure and Its Impact on Prognosis. September 15, 2023 July 30, 2024
NCT04613206 Recruiting Phase 2 High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients January 11, 2021 April 30, 2025
NCT05945485 Recruiting Phase 1 A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults October 16, 2023 August 17, 2024
NCT06094010 Recruiting Phase 3 A Surveillance Study of Susceptibility to Baloxavir Marboxil in Participants With Influenza November 22, 2023 June 30, 2027
NCT02200276 Recruiting N/A Influenza Immunization in Adults Over Age 75 March 2014 June 2026
NCT04548518 Recruiting Phase 3 Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Elderly August 3, 2020 December 31, 2023
NCT05739474 Recruiting Phase 3 Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children January 19, 2022 December 30, 2023
NCT01056185 Recruiting Respiratory Virus Hospitalization Study (FLU 003 Plus) August 2009 December 31, 2024
NCT05045612 Recruiting Phase 4 Antibiotic Therapy in Viral Airway Infections January 13, 2022 November 2029
NCT04327791 Recruiting Phase 2/Phase 3 COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1) April 3, 2020 June 1, 2025
NCT05494047 Recruiting Phase 3 Phase Ⅲ, Clinical Trial to Compare an Inactivated Quadrivalent Influenza Vaccine and a Licensed Vaccine in Chile July 14, 2022 July 31, 2023
NCT06417762 Recruiting N/A Dime La VerDAD: Verify, Debunk, and Disseminate May 30, 2023 April 1, 2028
NCT05436184 Recruiting Influenza IMPRINT Cohort: Defining the Impact of Initial Influenza Exposure on Immunity in Infants October 17, 2019 December 31, 2028
NCT06048406 Recruiting N/A Effect of Health Education on Promoting Influenza Vaccination Health Literacy September 11, 2023 June 30, 2024
NCT04336020 Recruiting The DETECT(Digital Engagement & Tracking for Early Control, & Treatment) Study March 24, 2020 April 2025
NCT05291676 Recruiting Phase 2 Systems Investigation of Vaccine Responses in Aging and Frailty November 6, 2023 April 2027
NCT05517174 Recruiting Phase 4 A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Older Adults September 22, 2022 August 31, 2025
NCT06076421 Recruiting N/A Equity Evaluation of Fact Boxes on Informed COVID-19 and Influenza Vaccination Decisions - Study Protocol November 17, 2023 December 2024
NCT05968989 Recruiting Phase 1 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults August 9, 2023 December 16, 2024
NCT00828100 Suspended Phase 3 Comparison of Fluid Rapid Influenza and BinaxNOW Influenza A & B February 2009
NCT04544267 Suspended Phase 3 Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age September 15, 2020 July 2026
NCT04250311 Suspended Phase 3 Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults December 12, 2019 December 2024
NCT00826709 Suspended Phase 3 Prospective Evaluation of the Fluid Rapid Influenza Test February 2009
NCT00976027 Terminated Phase 3 Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older September 2009 April 2012
NCT02014168 Terminated Phase 1 Safety and Immunogenicity of Co-administration of Candidate Influenza Vaccine MVA-NP+M1 and Viroflu® Seasonal Influenza Vaccine January 2014 April 2014
NCT00979667 Terminated Phase 3 A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection October 2009 October 2010
NCT02014649 Terminated Phase 1/Phase 2 Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza November 2013 May 2014
NCT00610935 Terminated Phase 3 Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza January 2008 February 2008
NCT01456234 Terminated Phase 4 Time to Oseltamivir Access When Prescribed by Pharmacists Versus Physicians (ACCESS) November 2011 May 2013
NCT03020472 Terminated Phase 4 Kinetics of B-Cell Responses to Live, Attenuated Influenza Vaccine (LAIV) in Young Children Two Years of Age November 2008 January 2009
NCT03023709 Terminated Phase 4 Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers (SLVP032) September 2015 December 2015
NCT01003418 Terminated Phase 2 Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children November 17, 2009 November 25, 2010
NCT03028987 Terminated Phase 4 Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031) November 19, 2014 November 18, 2015
NCT04141917 Terminated Phase 4 Test-and-treat for Influenza in Homeless Shelters November 15, 2019 March 31, 2021
NCT01014091 Terminated Phase 3 Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children December 1, 2009 January 14, 2011
NCT00970606 Terminated N/A STIP: Statin Trial for Influenza Patients October 2009 July 2011
NCT01032837 Terminated Phase 4 A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain November 2009 October 2010
NCT00436124 Terminated Phase 4 A Study of Tamiflu (Oseltamivir) Treatment in Laboratory-Confirmed Influenza. January 2007 April 2007
NCT01053663 Terminated Phase 1 A Study of Intravenous Oseltamivir [Tamiflu] in Infants With Influenza January 2011 January 2013
NCT01056380 Terminated Phase 2 Study of Nitazoxanide in Adults With Acute Uncomplicated Influenza January 2010 December 2010
NCT04377165 Terminated N/A Innovative Tool to Limit Spread of COVID 19 in Residential Aged Care Facilities May 6, 2020 August 26, 2020
NCT03300362 Terminated Phase 2 Improved Novel VaccIne CombinaTion InflUenza Study October 13, 2017 October 31, 2018
NCT01673425 Terminated N/A Evaluating Immune Response to Seasonal FluMist in Healthy Adults September 2012 December 2012
NCT01690637 Terminated Phase 4 Panama and El Salvador Children's Oseltamivir Study September 2012 November 2013
NCT02385123 Terminated Phase 4 Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers April 1, 2015 December 31, 2020
NCT00396305 Terminated Phase 4 Th1 Response to Influenza: Aging and Vaccine Efficacy November 2006 January 2008
NCT00383071 Terminated Phase 2 Development of Immune Globulin Treatment for Avian Flu August 2006 December 2014
NCT01160237 Terminated Phase 3 Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM August 2010 February 2011
NCT01171157 Terminated Effectiveness of Flu Vaccination and Burden of Illness Among Community-dwelling Elderly With Influenza Like Illness in Brazil May 26, 2009 June 29, 2009
NCT02485639 Terminated Phase 4 Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination December 23, 2015 March 31, 2020
NCT01194297 Terminated Phase 4 Study of Live, Attenuated Influenza Vaccination in Preterm and Full-Term Infants August 2010 May 2012
NCT01195779 Terminated Phase 2 Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children September 30, 2010 March 22, 2011
NCT04664075 Terminated Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19) January 25, 2021 April 30, 2022
NCT02561169 Terminated Phase 4 A Trial of Oseltamivir in High-Risk Patients Presenting to the Emergency Department With Influenza December 2015 March 2016
NCT01224795 Terminated Phase 3 A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza. October 2010 November 2010
NCT03686514 Terminated Phase 4 The Impact of Imprinting and Repeated Influenza Vaccination on Adaptive Immunity, Transcriptomics, and Metabolomics October 22, 2018 June 20, 2020
NCT04912180 Terminated Apple Respiratory Study April 6, 2021 June 9, 2021
NCT02883426 Terminated Phase 1 Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease September 2016
NCT01375985 Terminated Phase 1 Safety Study of Single Administration Intravenous Treatment for Influenza June 2011 November 2011
NCT03880474 Terminated Phase 2 Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults March 18, 2019 January 21, 2020
NCT03004040 Unknown status Protection From Influenza: Determining the Impact of Prior Infection December 2016 January 2019
NCT01698177 Unknown status Phase 4 Optimizing Influenza Vaccination in Surgical Oncology Patients October 2011 July 2013
NCT01286285 Unknown status Surveillance of Influenza in Paediatric Intensive Care Units in Bavaria October 2010 March 2012
NCT04048369 Unknown status N/A Impact of Influenza/RSV PCR Point-of-care Testing in the Emergency Medical Service. January 17, 2019 December 31, 2019
NCT01299142 Unknown status Phase 1 Safety and Pharmacokinetics Study of Human Monoclonal Antibody (FGI-101-1A6) January 2011 October 2011
NCT01481467 Unknown status N/A Evaluation of an Influenza Vaccination Implementation Strategy for Hospital Health Care Workers April 2009 March 2012
NCT03010410 Unknown status Platelet Immune Responses in Aging and Influenza and Sepsis (INVACS) December 21, 2014 December 2019
NCT00936013 Unknown status Phase 4 Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1)Pneumonia: Multi-centre, Prospective, Randomized Controlled Study August 2009 July 2011
NCT05095844 Unknown status National Vaccine Adverse Event Reporting Survey and Etiology March 15, 2022 April 1, 2024
NCT00798421 Unknown status Study to Evaluate Nosocomial Transmission of Influenza December 2008 May 2009
NCT02762851 Unknown status Phase 4 Influenza Vaccine To Prevent Adverse Vascular Events (RCT-IVVE) June 2016 December 2020
NCT03754686 Unknown status Phase 4 Oseltamivir Versus Paracetamol for Influenza-like Illness During the Influenza Season February 10, 2019 July 1, 2022
NCT05019456 Unknown status N/A Exercise and COVID-19 Viral T-cell Immunity March 9, 2021 December 25, 2022
NCT01444482 Unknown status Phase 1 Study of Parenterally Administrated Adjuvanted Seasonal Influenza Vaccine in Healthy Elderly Volunteers May 2011
NCT02871206 Unknown status Phase 4 Adjuvanted Inactivated Vaccine Versus Inactivated Influenza Vaccine in Hutterite Children November 2016
NCT00294788 Unknown status Phase 1/Phase 2 Evaluation of the Safety and Effectiveness of a Probiotic Bacterium to Boost the Immune Response to Influenza Vaccines March 2006 January 2007
NCT01322516 Unknown status Outcomes of Pandemic Influenza in Pregnancy September 2009 September 2012
NCT03787459 Unknown status Phase 3 Severe Influenza Trial of ARbidol January 18, 2019 August 1, 2020
NCT01651663 Unknown status Phase 4 A Study of Arbidol (Umifenovir) for Treatment and Prophylaxis of Influenza and Common Cold September 2011 June 2015
NCT02897011 Unknown status N/A 2-week dc of MTX and Influenza Vaccination in RA September 2016 August 2017
NCT00417560 Unknown status Phase 1/Phase 2 Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses January 2007 January 2013
NCT00410176 Unknown status N/A A Randomized, Controlled, Unblinded, Clinical Trial of the Acceptability and Efficacy of Non-Pharmaceutical Methods in Preventing Spread of Influenza Within the Family January 2007
NCT01096238 Unknown status Follow-up of Immunogenicity of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Healthy Volunteers After 6 Months March 2010
NCT04471038 Unknown status Phase 1 Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants July 29, 2020 December 2021
NCT01078779 Unknown status Phase 2 The Chloroquine for Influenza Prevention Trial November 2009 August 2010
NCT05389137 Unknown status Phase 4 To Identify the Immunogenicity and Safety of QIV in Children Aged 3-8 Years March 2, 2022 October 2022
NCT05315024 Unknown status N/A Influenza Vaccine With Topical Imiquimod in Influenza Vaccine Non-responsive Children April 30, 2022 October 30, 2023
NCT01677689 Unknown status Phase 2 Study to Investigate the Efficacy and Safety of Apomivir® September 1, 2018 October 31, 2019
NCT01067404 Unknown status TIV Infant/Toddler Response Evaluation (TITRE)- Follow-up & Focus on Influenza B February 2010
NCT01066377 Unknown status N/A PRIMAGE (Probiotics, Immunity and Ageing) April 2010 January 2013
NCT03331991 Unknown status Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel September 28, 2016 July 2019
NCT03830684 Unknown status Phase 2 A Randomized, Double-blind, Placebo-controlled, Multicenter and Phase Ⅱa Clinical Trial for the Effectiveness and Safety of Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever February 1, 2019 October 31, 2019
NCT01424371 Unknown status Adjuvanted Influenza Vaccine Effectiveness in the Elderly (65+Yrs) November 2011 June 2013
NCT02434276 Unknown status Phase 2 Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years May 2015 June 2016
NCT03365336 Unknown status N/A Influenza Management With Polyherbal Formulation February 1, 2018 May 15, 2018
NCT05093998 Unknown status Phase 3 Study Evaluating the Efficacy and Safety of AV5080 in Patients With Uncomplicated Influenza January 15, 2022 July 31, 2023
NCT03367624 Unknown status Epidemiology of Post-influenza Bacterial Pneumonia Due to a Panton-Valentine Leukocidin Positive Staphylococcus Aureus October 1, 2017 March 2018
NCT01055990 Unknown status Phase 2 Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients October 2009 May 2010
NCT02015494 Unknown status Phase 1 Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention March 2014 December 2015
NCT01053377 Unknown status Phase 4 A Randomised Controlled Trial on the Effect of Post-exposure Oseltamivir Prophylaxis on Influenza Transmission in Nursing Homes December 2009 December 2013
NCT01719874 Unknown status Phase 2 Influenza Virus Challenge Study to Test Monoclonal Antibody TCN-032 as a Treatment for Influenza August 2012 March 2013
NCT04297462 Unknown status N/A Different Regimens in Influenza Postexposure Chemoprophylaxis in Children November 17, 2016 December 31, 2020
NCT03413228 Unknown status Nosocomial Influenza Surveillance 2018 - 2022 February 2018 June 2022
NCT01622491 Unknown status Effectiveness of H1N1 Influenza Vaccines in Manitoba, Canada June 2012 December 2013
NCT01040078 Unknown status Phase 3 Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month December 2009 June 2010
NCT01985620 Unknown status N/A The Impact of a Short Intervention During RSV Prophylaxis on Influenza Vaccination Rate. November 2013
NCT04223544 Unknown status Incidence of Influenza Infections and Determination of Vaccination Coverage Rate Among Healthcare Workers January 13, 2020 April 3, 2020
NCT01432340 Unknown status Seasonal Influenza Vaccine Effectiveness Study in Kenya June 2010 March 2013
NCT02247362 Unknown status Phase 1/Phase 2 Study of Safety and Immunogenicity of a Quadrivalent Influenza Vaccine in Healthy Adults Age 65-75 Years November 2014 March 2016
NCT05277298 Unknown status Household Study of COVID-19, Influenza and RSV Burden, Transmission Dynamics and Viral Interaction in South Africa July 1, 2020 December 31, 2022
NCT00155974 Unknown status N/A Rapid Vaccination of Hard-To-Reach Populations February 2004 October 2005
NCT02232945 Unknown status Phase 4 Banlangen Granules Anti-seasonal Influenza Study April 2012 November 2016
NCT01207518 Unknown status N/A Cluster RCT - Evaluating Effectiveness of a Guide and Tools for Influenza Immunization Campaign Planners August 2010 August 2012
NCT02933723 Unknown status N/A Immunogenicity of Influenza Vaccine in Long Term Care October 2016 September 1, 2021
NCT01582633 Unknown status Phase 2/Phase 3 Assessment of Needle-free Disposable-syringe Jet Injector (DSJI) ID Dose-sparing of Pandemic A H1N1 Influenza Vaccine July 2012 September 2012
NCT01026350 Unknown status Phase 1 Safety and Efficacy of Oral Colostrum Derived Anti Influenza Antibodies in Healthy Volunteers January 2010
NCT02572583 Unknown status Phase 1/Phase 2 A Clinical Study of Treating Influenza With Liugan Shuangjie Heji November 2014 November 2016
NCT04143451 Unknown status Phase 3 Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients October 23, 2019 March 31, 2023
NCT00613184 Unknown status N/A Comparison of Nylon Flocked Swabs and Saline Aspirates for Detection Respiratory Viruses November 2006 January 2008
NCT04131296 Unknown status Lung Bacteriobiota and Influenza Mortality December 1, 2019 April 30, 2020
NCT01227798 Unknown status Phase 1/Phase 2 Safety and Efficacy Study of Interferon to Treat Patients Hospitalized for Influenza November 2010 November 2011
NCT02589574 Unknown status N/A Improving Influenza Vaccination Rates in Nurses Through Text Message Reminders : a RCT November 2015 August 2016
NCT04110990 Unknown status Retrospective Observational Study on the Epidemiological Characteristics of Influenza Patients October 2019 October 2020
NCT01815268 Unknown status Phase 4 High-Dose Influenza Vaccine in Nursing Homes February 2013 September 2018
NCT01235000 Unknown status TIV Infant/Toddler Response Evaluation - Follow-up for Influenza B Boost October 2010
NCT00758212 Unknown status N/A Influenza Vaccination at a Reduced Dose Using Mesotherapy in HIV/AIDS Patients at the Hadassah AIDS Center, Jerusalem November 2008 April 2009
NCT01006681 Unknown status Phase 2 Vaccination Against Influenza H1N1 in Rheumatic Diseases November 2009 April 2010
NCT00216242 Unknown status Phase 3 Study of the Protective Effect of an Injectable Influenza Vaccine Against Influenza Illness in Adults Under 50 y.o. September 2005 May 2007
NCT01512056 Unknown status Phase 4 Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine,Formulation 2011-2012, in Dialysis Patients October 2011 March 2012
NCT02658409 Unknown status Phase 3 A Multicenter, Double-blind, Parallel, Non-inferiority, Phase III Study November 2015
NCT01258842 Unknown status Phase 3 Bifidobacterium Lactis HN019 Supplementation for Prevention of Influenza Infection in Healthy Adults December 2010 May 2011
NCT02662426 Unknown status Phase 3 Lingdancao Granules in the Treatment of Seasonal Influenza April 2016 December 2017
NCT02665871 Unknown status Phase 1 Safety Study of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in Chinese Adults Aged 3 Years and Older March 2016 September 2016
NCT05144464 Unknown status Phase 4 A Clinical Trial of an Inactivated Quadrivalent Influenza Vaccine in Chinese Children Aged 3 to 8 Years September 19, 2021 April 30, 2022
NCT01150149 Withdrawn N/A Evaluating Modes of Influenza Transmission Between Humans March 2009 June 2010
NCT06163677 Withdrawn A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza. January 17, 2024 January 17, 2024
NCT03898973 Withdrawn Phase 4 Response to Inactivated Influenza Vaccine in Lymph Tissue and Blood April 11, 2019 November 17, 2023
NCT00486980 Withdrawn Phase 3 Intramuscular Peramivir for the Treatment of Uncomplicated Influenza
NCT02037282 Withdrawn Phase 1 A Phase 1, Open Label, Ascending Dose Cohort Study of the Pharmacokinetics of Anti-Influenza Hyperimmune Intravenous Immunoglobulin in Healthy Subjects January 3, 2014 December 2, 2014
NCT05035680 Withdrawn Phase 1 Proof of Concept Trial of Adjuvant Activity of SWE, a Squalene-based -Oil-in-water Emulsion July 14, 2022 November 25, 2023
NCT02282384 Withdrawn Phase 4 An RCT of Oseltamivir in Outpatients With CPD: A Pilot Study. October 2014 March 2015
NCT02177734 Withdrawn Phase 1 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age March 2016 May 2017
NCT00964951 Withdrawn Phase 2 CSL H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations November 2010
NCT00989274 Withdrawn Phase 2 Clinical Trial to Evaluate the Immunogenicity and Safety of the Vaccine Against Influenza A/H1N1 June 2010 July 2010
NCT01008956 Withdrawn Phase 2 Safety and Immune Response of One-Dose of Candidate H1N1 Influenza Vaccine GSK2340274A in Adults April 2010 October 2010
NCT01992276 Withdrawn Phase 2 Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection December 2013 February 2015
NCT01270685 Withdrawn 2009 H1N1 Pandemic and Seasonal Influenza in SCI/D: Infection Control Strategies July 2010 August 2011
NCT01063933 Withdrawn Phase 1/Phase 2 Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With Influenza December 2012
NCT02000466 Withdrawn FluLaval® Quadrivalent Pregnancy Registry November 2013 May 2018
NCT01045564 Withdrawn Phase 2 Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure January 2011 February 2013
NCT04761692 Withdrawn N/A Increasing COVID-19, Influenza, and Pneumonia Vaccine Uptake October 1, 2022 December 31, 2026
NCT00342940 Withdrawn Phase 2 Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older October 2006
NCT00873886 Withdrawn Phase 1 A Study of the Pharmacology of Oseltamivir (Tamiflu) in Pregnancy April 2009 September 2010
NCT03903718 Withdrawn Phase 2 Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza April 3, 2020 October 9, 2020
NCT00866580 Withdrawn Phase 3 A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine May 2010 July 2011
NCT00335855 Withdrawn Phase 1 Pharma-Pen (Formerly Innoject) Auto-injectory TIV October 2006
NCT01037634 Withdrawn Phase 2 Safety and Efficacy of Oseltamivir in Children Younger Than One Year of Age March 2010
NCT00966342 Withdrawn Phase 1 Rapid Evaluation of Seasonal Influenza Vaccine August 2009 November 2009
NCT01546935 Withdrawn Phase 2/Phase 3 Oseltamivir for Influenza Lower Respiratory Tract Infection in Children Under One December 2012 December 2014
NCT01146353 Withdrawn Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy February 2010 February 2011
NCT03327987 Withdrawn Early Flu Shots in SOT May 7, 2019 May 7, 2019
NCT04806529 Withdrawn Phase 2/Phase 3 An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and Older December 15, 2020 April 9, 2022
NCT00766285 Withdrawn Phase 2 High Dose Influenza in Immunosuppressed Subjects September 2010
NCT03884296 Withdrawn Phase 4 Response to Live Attenuated Influenza Vaccine in Tonsillar Tissues and Blood April 15, 2019 November 17, 2023
Disase is a (Disease Ontology)
DOID:934
Cross Reference ID (Disease Ontology)
ICD10CM:J11.1
Cross Reference ID (Disease Ontology)
ICD9CM:487
Cross Reference ID (Disease Ontology)
MESH:D007251
Cross Reference ID (Disease Ontology)
NCI:C53482
Cross Reference ID (Disease Ontology)
SNOMEDCT_US_2023_03_01:155559006
Cross Reference ID (Disease Ontology)
UMLS_CUI:C0021400
Exact Synonym (Disease Ontology)
flu
Exact Synonym (Disease Ontology)
influenza with non-respiratory manifestation
Exact Synonym (Disease Ontology)
Influenza with other manifestations